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1 Introduction 
The most abundant life form on earth are prokaryotes and humans are adapted to a life in 
symbiosis with this unseen majority of microorganisms (Whitman et al. 1998). Several skin 
locations like the forearm, palm, index finger, back of the knee and sole of the foot are 
inhabited by highly diverse communities (Costello et al. 2009, Hooper et al. 2001). Compared 
to all other body sites the human gastrointestinal tract (GIT) harbors the largest and most 
diverse community of microbes (Costello et al. 2009; Eckburg et al. 2005). The amount of 
microbes (1014) inhabiting the intestinal tract of a human adult outnumbers the human cells by 
a factor of ten and the hundreds of species native to the colon, where microbial richness and 
abundance are maximal, contain 100-fold more genes than does the human genome. The 
amount of bacteria within the GIT increases from the stomach to the rectum, whereas each 
region harbors a specific composition of bacteria. The highest density of 1011 - 1012 bacteria 
per gram colonic content can be found within the large intestine (Hooper et al. 2001; 
Whitman et al. 1998; Franks et al. 1998). The healthy microbiota can usually be assigned to 
four main phyla: Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria. Only a 
minority of the intestinal bacteria are cultivable (10-30%), but culture-independent methods 
estimated between 800 and 1000 different bacterial species or phylotypes and more than 7000 
different bacterial strains to be present in the human GIT (Bäckhed et al. 2005; Eckburg et al. 
2005). The majority within the healthy GIT are anaerobic bacteria, but also fungi, archaeae 
and some protozoa can be found. Within the kingdom of archaeae Methanobrevibacter smithii 
is the predominant if not the only species of methanogens in the human intestine (Bäckhed et 
al. 2005; Eckburg et al. 2005). The lack of species diversity in the intestinal archaeae, in 
comparison to the diversity among bacteria, is striking but as yet unexplained. 
1.1 The human microbiota: A stable fingerprint-like consortium 
Several studies have shown that each individual retains a distinct microbiota profile over time. 
The microbial composition differs between individuals, but twins have a more similar 
bacterial community structure than unrelated individuals (Turnbaugh et al. 2009; Zoetendal et 
al. 2001). Furthermore some authors assume a core microbiome. Besides rare taxa that vary 
immensely there seems to be a common set of abundant microbial species that are shared 
among all / or most individuals with twins sharing significantly more phylotypes. However, 
this core may exist at the level of shared functional genes and metabolic pathways rather than 
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shared taxa (Qin et al 2010; Tap et al. 2009; Turnbaugh et al 2009). The temporal changes in 
the bacterial community structure within an individual are smaller in comparison to the 
differences between individuals. Maintaining habits result in a relatively stable microbiota 
over time (Claesson et al. 2011; Costello et al. 2009; Mai et al. 2004; Franks et al. 1998; 
Zoetendal et al. 1998). The diversity and the fingerprint-like individuality of the microbial 
composition as well as possible dynamics within can partly be explained by age, host 
genotype and microbial interactions, but also by life-style factors like diet and exercise. With 
regard to the host genotype it could be shown that obese leptin deficient mice had a lower 
abundance of Bacteroidetes and a proportional increase in Firmicutes as shown by Ley et al. 
(2005). Mutations in Nod2 resulted in a significant increase in Firmicutes and Bacteroidetes 
in mice and human (Rehman et al. 2011, Petnicki-Ocwieja et al. 2009). Furthermore the 
FUT2 genotype explains differences in the human microbial composition (Rausch et al. 
2011). Variations based on diet and other environmental factors seem to influence the luminal 
microbiota in a greater amount than the mucosa-associated microbiota. The epithelial wall and 
the overlying mucus layer may possibly maintain a more stable environment than present in 
the lumen (Gillevet et al. 2010; Eckburg et al. 2005; Zoetendal et al. 2002). 
1.2 Gut bacteria are workaholics 
The microbiota of the human GIT is involved in maintaining human health and 
gastrointestinal tract homeostasis. It regulates the gut epithelial development and survival by 
stimulation of proliferation, angiogenesis and epithelial restitution (Mai et al. 2010; Neish et 
al. 2009). The gut bacteria are responsible for the digestion of otherwise indigestible dietary 
polysaccharides. Dietary fibers and host intestinal mucins are fermented into simple sugars, 
short chain fatty acids and other nutrients that can be absorbed and are used as energy source 
by the host. For example acetate is important for the muscle, heart and brain cells, propionate 
is used in host hepatic neoglycogenic processes, whereas butyrate is important for 
enterocytes. A number of amino acids are indispensable to humans and can be provided by 
bacteria as well as essential vitamins like vitamin K, vitamin B12 and folic acid. The gut 
bacteria are also involved in bile acid metabolism and bile acid recirculation (Mai et al. 2010; 
Qin et al. 2010). Furthermore, the gut bacteria play a role in the immunmodulation. They 
prevent the colonization as well as the crossing of the mucosal barrier by pathogens via 
modulation of innate defenses such as inducing the epithelial production of α-defensins and 
mucins (Hooper et al. 2001). If the integrity of the mucosal barrier is broken by cytoinvasive 
bacteria, the bacterial components, for instance lipopolysaccharides (LPS), peptidoglycans 
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and flagellin, are recognized by pattern recognition receptors (PRRs) like the membrane-
bound toll-like receptors (TLRs) or intracellular Nod-like receptors (NLRs). This results in a 
protective signal cascade which aims to restore the integrity of the epithelial barrier. However, 
it has not been clarified completely how the intestinal epithelial cells are able to distinguish 
between pathogenic and nonpathogenic bacteria (Gomez-Llorente et al. 2010; Takeda and 
Akira 2005). 
1.3 Perturbation of the microbiota 
In a healthy host there is a balance between members of the microbiota, such that potential 
pathogenic and non-pathogenic organisms can be found in apparent harmony. During 
infection, this balance can become disturbed. Bacterial imbalance, so-called dysbiosis, occurs, 
leading to often dramatic changes in the composition of the microbiota resulting in 
pathologies such as inflammatory bowel disease (IBD) (Rehman et al. 2010; Ott et al. 2004). 
Several studies have implicated intestinal communities with diseases ranging from allergies to 
late-onset autism, IBD and cancer. For most bacterial infections, broad-spectrum antibiotics 
are used, eradicating the pathogens as well as the non-pathogenic members of the microbiota. 
Thereby they disrupt the natural microbiota with a simultaneous decrease in bacterial load and 
a transient reduction in taxonomic richness, diversity and evenness of the community for 
some time. This can lead to a substantial delay in the restoration of a healthy microbiota and 
result in intestinal problems, such as antibiotic-associated diarrhea (Jernberg et al. 2007; 
Jakobsson et al. 2010; Robinson et al. 2010). Disturbances of the metabolism and absorption 
of vitamins, alteration of susceptibility to infections and overgrowth of yeast and/or 
Clostridium difficile can follow so that there is a shift from potentially beneficial and health-
promoting bacteria (like Lactobacilli and Bifidobacteria), towards harmful pathogenic 
microorganisms (such as Clostridia, sulphate-reducers and proteolytic Bacteroides species). 
This makes the host even more susceptible to infections by transient enteropathogens like 
Salmonella, Campylobacter and certain species of Escherichia coli and Listeria (Fooks and 
Gibson 2002). An additional harmful disadvantage of antibiotics is the increased prevalence 
in antibiotic resistance and the potential spreading of resistance genes to pathogenic bacteria, 
thereby reducing the possibility of successful future antibiotic treatments. 
The antibiotic used in this study is paromomycin (brandname: Humatin®, Pfizer). 
Paromomycin is an aminoglycoside and active against most Gram-negative and many Gram-
positive bacteria as well as some protozoa and cestodes. Like most aminoglycosides it binds 
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to the 30S-subunit of the bacterial ribosome and thereby impairs the protein synthesis. Orally 
administered paromomycin is only poorly absorbed. It is used as a treatment against visceral 
leishmaniasis and amebiasis, but also for the reduction of the microbiota before surgery. In 
this study it was used to completely clean the bowel to enable a better look onto the resilience 
of the gut microbiota (Davidson et al. 2009). 
1.4 The resilience phenomenon 
Usually the microbiota exerts a high self-regeneratory capacity, which describes the ability to 
restore the microbial equilibrium after an external perturbation, for example antibiotic 
treatment, also referred to as the resilience phenomenon. It is known that antibiotics cause 
short-term changes in the composition of the normal human microbiota, but long-term 
consequences have also been shown. Antibiotic perturbation is mainly characterized by a 
decreased colonization resistance of the commensal microbiota, which leads to varying states 
of disease as well as to the appearance of antibiotic-resistant strains. The extent of the 
antibiotic-induced alterations in the microbiota depends on several factors: the spectrum of 
the agent, dosage and duration of the treatment, route of administration and the 
pharmacokinetic and pharmacodynamic properties of the agent. It has been shown that the 
taxonomic composition of the community closely resembles its pretreatment state between 
one and three months after the end of the treatment, but that specific populations in the 
community were significantly affected and failed to recover within six months or up to two or 
even four years (Jakobsson et al. 2010; Antonopoulos et al. 2009; Dethlefsen et al. 2008). 
Jakobsson et al. (2010) further investigated the erm(B) gene, which encodes a ribosomal 
methylase that modifies the 23S rRNA, thereby preventing the antibiotic from binding and 
resulting in resistance to this antibiotic. The erm(B) gene levels increased dramatically by 
three to five orders of magnitude after starting an antibiotic treatment with clarithromycin, 
metronidazole and omeprazole. These high levels of the erm(B) gene were still distinct after 
four years post treatment, indicating that antibiotic resistance can persist for very long 
periods. Even studies in healthy humans, in which clindamycin was administered for a few 
days, could show that although there was a normalization of the overall intestinal flora and the 
number of species returned to pre-treatment levels within three months, specific populations 
within the community (especially Bacteroides) were significantly affected and disturbed in 
terms of richness and diversity. These severe disturbances even persisted for more than two 
years after treatment. Moreover, in these studies a dramatic and persistent increase in the 
levels of specific resistance genes towards the given antibiotic was detected (Jernberg et al. 
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2007, Löfmark et al. 2006). Another study showed that after five days of oral administration 
of amoxicillin, the fecal microbiota was already markedly altered within two to three days 
after beginning of antibiotic treatment. However, the dominant microbiota needed at least 60 
days in most of the study participants to return to the initial composition (De La Cochetiere et 
al. 2005). Therefore it seems that the healthy human microbiota has a kind of regeneratory 
capacity, whereas the complete bacterial diversity is difficult to re-establish and may take 
time. The resilience in diseased individuals can be even more dramatic. 
1.5 Probiotics: The possible miracle drug 
Probiotics in general are defined as “live organisms which when administered in adequate 
amounts confer a health benefit on the host” (World Health Organization). There are several 
criteria an organism has to fulfill to be a probiotic: (1) The organism must be fully identified 
referring to genus, species and strain. (2) It must be safe for consumption, not pathogenic and 
is not allowed to carry antibiotic resistance genes. (3) The organism has to survive the 
intestinal tract (acid and bile tolerant), adhere and not degrade to the mucosal surface and 
colonize the intestine. (4) The probiotic organism has to possess documented health effects (at 
least one phase 2 study documenting benefit), produce antimicrobial substances and 
antagonize pathogenic bacteria. (5) Finally it must be stable during process and storage. 
Bacteria such as lactic-acid bacteria (LAB) and Escherichia coli strains (e. g. E. coli Nissle 
1917), as well as yeast species including Saccharomyces boulardii are categories of probiotics 
that are in use today. Probiotics are available in a wide variety of formulations ranging from 
tablets and powders to yoghurts, milk and juices (Verna and Lucak 2010). The indication for 
using probiotics is the potential decrease of the pathogen density and thereby the restoration 
and maintenance of the gut microbial homeostasis and the patients tolerance to the own 
commensal flora. Probiotics are used as treatments for a variety of gastrointestinal disorders 
like antibiotic-associated diarrhea, Clostridium difficile colitis, infectious diarrhea and IBD 
(Avadhani and Miley 2011; McFarland 2009; D´Souza et al. 2002). Therapy of allergic 
diseases (e.g. atopic dermatitis), urinary tract infections and the prevention of dental caries or 
respiratory infections further show an increasing frequency of probiotic use (Tang et al. 2010; 
MacPhee et al. 2010; Bonifait et al. 2009). 
The two major types of IBD are Ulcerative Colitis (UC) and Crohn´s Disease (CD). 
Medicating UC with probiotics resulted in enhancements in disease activity indices and 
cytokine profiles and in an (re)induction or maintenance in remission (Tursi et al. 2010; 
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Bibiloni et al. 2005). In CD the actual data are controversial and most of the studies failed to 
show a benefit of probiotic administration, which is not completely unexpected regarding that 
there is only little evidence of the microbial imbalance being the primary course of this 
disorder (Reid et al. 2011; Isaacs and Herfarth 2008). However a replicated evidence for the 
use of probiotics exists in the prevention and treatment of pouchitis (Verna and Lucak 2010; 
Kühbacher et al. 2006). The exact mechanism by which the probiotics function is not yet fully 
understood. An antagonistic activity against the pathogenic bacteria is discussed in terms of a 
competition for the adherence to binding sites and nutrients. Moreover, the fermentation of 
the nutrients results in an acidification of the colon which is also effective against pathogenic 
bacteria. Probiotics seem to inhibit the translocation of pathogenic bacteria and to stabilize the 
epithelial barrier function also by stimulating the production of mucin and bacteriocins as 
protective substances. Further, the gastrointestinal immunity can be modulated by altering the 
immune functions like the stimulated secretory IgA production and cytokine profiles like the 
induction of IL-10 as well as the downregulation of proinflammatory cascades (Verna and 
Lucak 2010; Borchers et al. 2009; Vanderpool et al. 2008; Cotter et al. 2005; Drakes et al. 
2004). Yet the exact temporal sequence of colonization events of an administered probiotic 
that subsequently alters the microbiota and may result in an (beneficial) effect remains 
unclear. The behavior and possible effects of one probiotic strain cannot automatically be 
generalized for other strains. Some bacteria seem to result only in transient effects and are 
resistant to colonization. They persist only as long as they are ingested and rapidly disappear 
once the treatment is stopped. 
The probiotic used in this study is VSL#3 (VSL Pharmaceutical, Inc. (Pfizer)). It is a 
combination of four different Lactobacillus species (L. casei, L. plantarum, L. acidophilus, L. 
delbruekii), three Bifidobacterium species (B. longum, B. breve and B. infantis) and one strain 
of Streptococcus thermophilus. VSL#3 is a dietary supplement, which is approved for the 
restoration of the gut after mucosal infection, for the relief of abdominal bloating and pain in 
diarrhea-predominant irritable bowel syndrome and for the sustainment of remission in 
pouchitis and ulcerative colitis in adults and children (Guandalini et al. 2010; Miele et al. 
2009; Kühbacher et al. 2006; Bibiloni et al. 2005; Mimura et al. 2004; Kim et al. 2003; 
Gionchetti et al. 2000). On the molecular basis it is described that VSL#3 has an increasing 
effect on the epithelial barrier function and barrier integrity via an induction of 
proinflammatory pathways like NF-κB, AP-1 and MAPKs as well as on the mucin expression 
(Schlee et al. 2008; Otte et al. 2004). This occurs in combination with a reduction in mucosal 
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secretion of TNF-α and IFN-γ (Jijon et al. 2004; Madsen et al. 2001). Further VSL#3 is able 
to decrease the LPS induced production of IL-12 and thereby diminishing the 
proinflammatory effects of LPS, to enhance the IL-10 release by dendritic cells from blood 
and intestinal tissue and to induce the β-defensin production of enterocytes (Schlee et al. 
2008; Drakes et al. 2004; Hart et al. 2004; Ulisse et al. 2001). 
1.6 Analysis of microbial profiles 
To identify microbial profiles in a culture-independent way it is common to analyse the 16S 
rRNA gene sequence. The 16S rRNA gene is a section of the prokaryotic DNA found in all 
bacteria and archaeae. The prokaryotic 70S ribosome of bacteria and archaeae consists of two 
subunits, the large 50S subunit (LSU) and the small 30S subunit (SSU). These two subunits 
enclose the mRNA during translation. The SSU is encoded by the 16S rRNA gene ("r" stands 
for ribosomal), the LSU is encoded by the 23S rRNA and the 5S rRNA gene. Therefore it is 
distinct from the 18S rRNA gene, which is the eukaryotic equivalent. The 16S rRNA gene is 
relatively short (1542 nucleotides) which makes it easier to sequence compared to many other 
genes. It can be subdivided into highly conserved primer binding sites and nine variable 
regions (V1-V9) (Baker et al. 2003). The variable regions depict species-specific signatures. 
The 16S rRNA gene can directly be isolated by PCR with universal primers targeting the 
conserved regions. Based on the amplification of the 16S rRNA gene the sequencing 
according to the method of Frederick Sanger as well as the 454 pyrosequencing approach was 
performed in this study. Additionally, quantitative real-time PCR was conducted. 
 
Methods like TTGE (temporal temperature gradient gel electrophoresis) are rapid methods to 
investigate the dominant bacteria within a sample, but offer only a low taxonomic resolution 
of the less abundant community members. Sequencing in general has the advantage of a 
deeper insight into microbial profiles on a finer taxonomic scale. For the Sanger sequencing 
as well as for the pyrosequencing approach DNA and/or RNA can be used. The PCR primers 
bind to the conserved regions of the 16S rRNA or the 16S rRNA gene and amplify the 
variable regions in between. 
The sequencing according to Frederick Sanger is performed due to the chain termination 
method (Sanger et al. 1977). The reaction closely resembles a PCR reaction, except for two 
key differences. Only one oligonucleotide primer is used, resulting in linear than exponential 
sequence amplification, and fluorescently labeled 2´,3´-didesoxynucleoside triphosphates 
(ddNTP) are included in the reaction in addition to dNTPs. The DNA polymerase requires a 
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free 3´ hydoxyl group for the enzymatic formation of a phosphodiester bond with new dNTPs, 
which is not present in ddNTPs. Therefore the elongation of a DNA fragment will be 
terminated when a ddNTP is incorporated. The incorporation of ddNTPs is a random 
procedure, which results in a mixture of fragments with differing length. The fragments are 
separated electrophoretically and are activated with a laser. Each of the four ddNTPs is 
labeled with another fluorescent dye, so that they fluoresce with different colors and can be 
identified with a detector. The chromatogram, which contains the trace of the color signals, 
directly shows the sequence of the bases of the sequenced DNA strand (Osborn and Smith 
2005). 
In contrast, the method of pyrosequencing observes the DNA polymerase in action. In this 
study a barcoded-tagged PCR approach was used. Each sample is tagged with an unique 
identifier, which enables the pooling of samples to a so-called library. Within the sequencing 
process individual nucleotides are flowed in a fixed order. Each incorporation of one (or 
more) nucleotide(s) complementary to the template strand results in a release of 
pyrophosphate (PPi). Pyrophosphate is converted into adenosinetriphosphate (ATP) by the 
ATP-sulfurylase. ATP then activates the luciferase reaction, thereby converting luciferin into 
oxyluciferin resulting in a detectable light signal, which is recorded by the CCD camera 
within the instrument. The signal strength is proportional to the number of nucleotides 
incorporated in a single nucleotide flow. If the nucleotide does not fit there is no light signal. 
Based on the sequences generated by the two different methods a first denoising step is 
performed to remove low quality sequences. The cleaned sequences are aligned and those that 
do not fit into the alignment properly are checked and potentially discarded. Furthermore, 
chimerical sequences are eliminated. The denoised dataset can then be analysed. For a first 
rough overview of the taxa that exist within the samples the sequences can be classified 
according to the reference sequences of the Ribosomal Database Project (RDP) (Wang et al. 
2009; Cole et al. 2008). For a deeper and more accurate analysis the sequences are assigned 
into operational taxonomic units (OTUs) due to the fact that the sequence-based recognition 
of uncultivated microbial populations is not equivalent to the traditional taxonomic 
classification. The OTUs can be defined at different levels of resolution, which are based on 
the homology between the sequences. An OTU level of 0.03 therefore indicates that all 
sequences within one OTU have a least a homology of 97%. Based on the OTU assignment, 
samples and treatment groups can then be compared. 
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1.7 Aim of the study 
The aim of this study is the investigation of the self-regeneratory capacity of the human 
colonic microbiota under placebo and probiotic therapy after an iatrogenic perturbation by an 
antibiotic agent. To characterise the microbial profiles under different treatment conditions at 
several timepoints, samples of the luminal as well as the mucosa-associated microbiota of 
twenty healthy individuals were taken at five and three different timepoints, respectively. The 
culture-independent analysis of the 16S rRNA and the 16S rRNA gene was used to generate 
clone as well as amplicon libraries, which result in the identification of treatment (antibiotic 
and placebo vs. probiotic) and/or timepoint-related microbial profiles. 
In detail the following questions shall be answered: 
 How does the microbial profile of a healthy microbiota change due to an 
antibiotic treatment? 
 Is the microbiota resilient? 
 When does the resilient microbiota resemble its pre-treatment state? 
 Is there a difference in the resilience with regard to the placebo and the probiotic 
therapy? 
 Is there a difference in the resilience between the luminal and the mucosa-
associated microbiota? 
 Is there a difference between the active and the present bacteria of the mucosa-
associated microbiota? 
The didesoxy chain termination method according to the method of Sanger was used for the 
sequencing of the 16S rRNA gene of the luminal microbiota. The mucosa-associated 
microbiota was sequenced according to the FLX pyrosequencing method. In addition, a real 
time PCR was performed for the relative quantification of the total bacteria as well as the two 
most abundant phyla. 
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2 Material and Methods 
2.1 Material 
2.1.1 Companies of purchased kits, chemicals, consumables and equipment 
The used kits, chemicals, consumables and equipment were purchased from the following 
companies: Ambion, (Austin, USA), Applied Biosystems (Foster City, USA), BD (Becton, 
Dickinson and Company, Heidelberg), Bio 101 (Heidelberg), Biorad (München), Biostep 
(Jahnsdorf), Eppendorf (Hamburg), Fermentas (St Leon-Rot), GE Healthcare (München), HJ 
Bioanalytik GmbH (Mönchengladbach), Invitrogen (Karlsruhe), Kendro (Hanau), Metabion 
(Martinsried), MP Biomedicals (Heidelberg), PeqLab (Erlangen), Pfizer (New York, USA), 
Qiagen (Hilden), Ratiolab (Dreieich), Roche (Basel, Switzerland), Roth (Karlsruhe), Sarstedt 
(Nürnbrecht), Sigma-Aldrich (St. Louis, USA), ThermoFisher Scientific (Waltham, USA), 
VSL Pharmaceuticals, Inc. (Gaithersburg, Maryland, USA), WTB binder (Tuttlingen). 
 
2.1.2 Kits and chemicals 
Table 2-1: Used kits and chemicals. 
Kit / chemical Producing company 
ABI PRISM® BigDye® Terminator v1.1 Cycle Applied Biosystems 
Sequencing Kit  
AllPrep DNA/RNA Mini Kit Qiagen 
FastDNA® SPIN for Soil Kit MP Biomedicals 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Min Elute® Gel Extraction Kit Qiagen 
Phusion Hot Start DNA Polymerase ThermoFisherScientific 
Qubit® ds DNA BR Assay Kit Invitrogen 
TOPO® TA Cloning Kit Invitrogen 
100 bp Gene Ruler Fermentas 
Ampicillin Sigma-Aldrich 
β-Mercaptoethanol Sigma-Aldrich 
DifcoTM Agar Noble BD 
dNTPs Peqlab 
Ethanol (99.9%) Sigma-Aldrich 
ExonucleaseI (E.coli) Fermentas 
Isopropanol (2-Propanol) Sigma-Aldrich 
LB-Medium (Luria/Miller) Roth 
N,N-Dimethylformamide Sigma-Aldrich 
Nuclease-Free Water Ambion 
Paromomycin (Humatin®) Pfizer 
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Kit / chemical Producing company 
Power SYBR® Green PCR Master Mix Applied Biosystems 
Proteinase K Fermentas 
RNase-Free DNase Set Qiagen 
RT-PCR Grade Water Ambion 
SephadexTM G-50 Superfine GE Healthcare 
Shrimp Alkaline Phosphatase Fermentas 
SOC Medium Invitrogen 
SYBR® Safe DNA gel stain Invitrogen 
TL Buffer Peqlab 
VSL#3® VSL Pharmaceuticals 
X-gal Fermentas 
 
2.1.3 Consumables and equipment 
Table 2-2: Used consumables and equipment. 
Consumable / equipment Producing company 
96-Deep-Well Plates HJ-Bioanalytik GmbH 
96 Well Multiply®-PCR Plate Sarstedt 
Biosphere® FilterTips Sarstedt 
Costar Thermowell® 96 Well PCR Plate ThermoFisher Scientific 
Coverfilms Ratiolab 
Disposable Gel Excision Tips Biostep 
Reaction tube (1.5 and 2 ml) Eppendorf 
Lysing Matrix E tubes MP Biomedicals 
Petri dishes Sarstedt 
QIAshredderTM Qiagen 
Qubit® assay tubes Invitrogen 
3730xl DNA Analyzer Applied Biosystems 
7900HT Fast Real-Time PCR System Applied Biosystems 
Centrifuge 5415 R Eppendorf 
FastPrep FP 120 Bio 101 
Gel Doc XR Biorad 
GeneAmp® PCR System 9700 Applied Biosystems 
GS FLX Instrument Roche 
Heraeus Labofuge 400 Kendro 
Incubator WTB binder 
Qubit® Fluorometer Invitrogen 
Thermomixer comfort Eppendorf 
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2.1.4 Primers 
Table 2-3: Used primers. 
Target Gene Name DNA-Sequence (5´-3´) 
Bacteria universal     
16S rRNA gene TPU1 AGA GTT TGA TCM TGG CTC AG 
V1-V4 805R GAC TAC CAG GGT ATC TAA TCC 
16S rRNA gene Pyro_27F CTA TGC GCC TTG CCA GCC CGC TCA GTC AGA 
V1-V2  TGA TCC TGG CTC AG 
for Pyrosequencing MIDX _338R CGT ATC GCC TCC CTC GCG CCA TCAG (MID) CAT 
  GCT GCC TCC CGT AGG AGT 
MID / barcode MID1_338R ACGAGTGCGT  MID28_338R ACTACTATG
 MID2_338R ACGCTCGACA MID29_338R ACTGTACAG
 MID3_338R AGACGCACTC MID30_338R AGACTATAC
 MID4_338R AGCACTGTAG MID31_338R AGCGTCGTC
 MID5_338R ATCAGACACG MID32_338R AGTACGCTA
 MID6_338R ATATCGCGAG MID33_338R ATAGAGTAC
 MID7_338R CGTGTCTCTA MID34_338R CACGCTACG
 MID8_338R CTCGCGTGTC MID35_338R CAGTAGACG
 MID10_338R TCTCTATGCG MID36_338R CGACGTGAC
 MID11_338R TGATACGTCT MID37_338R TACACACAC
 MID13_338R CATAGTAGTG MID38_338R TACACGTGA
 MID14_338R CGAGAGATAC MID39_338R TACAGATCG
 MID15_338R ATACGACGTA MID40_338R TACGCTGTC
 MID16_338R TCACGTACTA MID41_338R TAGTGTAGA
 MID17_338R CGTCTAGTAC MID42_338R TCGATCACG
 MID18_338R TCTACGTAGC MID43_338R TCGCACTAG
 MID19_338R TGTACTACTC MID44_338R TCTAGCGAC
 MID20_338R ACGACTACAG MID45_338R TCTATACTA
 MID21_338R CGTAGACTAG MID46_338R TGACGTATG
Target Gene Name DNA-Sequence (5´-3´) 
MID / barcode MID22_338R TACGAGTATG MID47_338R TGTGAGTAG
 MID23_338R TACTCTCGTG MID48_338R ACAGTATAT
 MID24_338R TAGAGACGAG MID49_338R ACGCGATCG
 MID25_338R TCGTCGCTCG MID50_338R ACTAGCAGT
 MID26_338R ACATACGCGT MID51_338R AGCTCACGT
 MID27_338R ACGCGAGTAT MID52_338R AGTATACAT
Insert of the vector pCR® 2.1 of the TOPO TA Cloning   
Vector pCR® 2.1 M13(16)F GTA AAA CGA CGG CCA G 
 M13(17)R CAG GAA ACA GCT ATG AC 
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Target Gene Name DNA-Sequence (5´-3´) 
Real-Time PCR     
All Bacteria Eub338F ACT CCT ACG GGA GGC AGC AG 
 Eub518R ATT ACC GCG GCT GCT GG 
Bacteroidetes Bact934F GGA RCA TGT GGT TTA ATT CGA TGA T 
 Bact1060R AGC TGA CGA CAA CCA TGC AG 
Firmicutes Firm934F GGA GYA TGT GGT TTA ATT CGA AGC A 
 Firm1060R AGC TGA CGA CAA CCA TGC AC 
β-Actin bActin_F GAT GGT GGG CAT GGG TCA G 
 bActin_R CTT AAT GTC ACG CAC GAT TTC 
 
The used primers were purchased from the company Metabion. 
 
2.1.5 Software and database 




MOTHUR version v.1.21.0 http://www.mothur.org/ 





SDS 2.3 Applied Biosystems 
Tinn-R http://sciviews.org/Tinn-R/ 
Ribosomal database project (RDP) http://rdp.cme.msu.edu/ 
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2.1.6 Study participants and study design 
Twenty healthy individuals were included in this study. The criteria for participation were 
between 18 and 50 years of age, no antibiotic or antimycotic treatment in the previous 6 
months, no probiotic therapy, no hospitalization, no diarrhea in the previous 6 months, no 
current infection, normal inflammatory markers, no relative or absolute contraindications 
against paromomycin (Humatin®) or VSL#3®. All individuals gave their written consent as 
approved by the local ethical committee of the Christian-Albrechts-University (CAU) of Kiel, 
Germany. 
Paromomycin (brandname: Humatin®, Pfizer) was administered at a dose of 4g per day over a 
period of three days to all twenty healthy individuals. After antibiotic therapy for three days, 
the group was split: half of the patients (n=10) were allocated to a probiotic therapy with 
VSL#3® (VSL Pharmaceuticals, Inc.) at a dose of 900 billion bacteria per day, the other group 
(n=10) received a placebo. Biopsies were sampled from the sigmoid colon before (day 0) and 
after the antibiotic treatment (day 4). After six weeks of probiotic or placebo treatment (day 
46) the study was completed by a last sigmoidoscopy. Stool samples were collected in parallel 
and at additional timepoints at day 14 and 28. Biopsies as well as fecal samples were stored at 
-80°C until further use. 
 
Figure 2-1: Study design. 
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2.2 Methods 
As previously described, the microbial profiles of the different timepoints were analysed by 
using the culture-independent approach of amplification and sequencing of the 16S rRNA 
gene which is found in all bacteria and archaeae. It can be subdivided into highly conserved 
primer binding sites and nine variable regions (V1-V9), which depict species-specific 
signatures. The 16S rRNA gene can directly be isolated by PCR with universal primers 
targeting the conserved regions. 
2.2.1 16S rRNA gene clone libraries from stool samples 
Five stool samples have been collected from each individual: At the beginning of the study 
(Day 0), after the three day antibiotic treatment (Day 4) and three more samples during the 
allocation to placebo or the probiotic VSL#3 (Days 14, 28 and 46). For the generation of the 
clone libraries the bacterial 16S rRNA gene encompassing the variable regions one to four 
(V1-V4) was amplified, ligated into the pCR® 2.1 vector, transformed into competent E. coli 
cells and finally Sanger sequenced. 
2.2.1.1 Extraction and purification of DNA from stool samples 
The extraction as well as the purification of the DNA from stool samples were performed with 
the FastDNA® SPIN for Soil Kit (MP Biomedicals). For the extraction of the stool-DNA a 
small amount of the thawed stool sample (around 50 mg) was filled into a 1,5 ml reaction tube 
(Eppendorf). To disrupt the cell walls 200 µl of TL buffer (PeqLab) and 25 µl of proteinase K 
(Fermentas) were added and the tube was stirred at 55°C for 2 h. The dissolved stool sample 
was transferred to a Lysing Matrix E tube and 978 µl sodium phosphate buffer and 122 µl MT 
buffer were added. After a homogenization step for 45 seconds at speed 4 in a FastPrep FP 
120 (Bio 101), a centrifugation step (13.000 rpm (rounds per minute), 30 seconds) for 
pelletizing the debris followed. The supernatant was transferred into a clean 2 ml reaction 
tube and 250 µl Protein Precipitation Solution (PPS) were added and mixed by inverting the 
tube several times. To pellet the precipitate the tube was centrifuged at 13.000 rpm for five 
minutes. 1 ml of the resuspended Binding Matrix was filled into a new 2 ml tube. After 
settling of the silica matrix 300 µl were discarded. The supernatant of the centrifuged sample 
was added and the reaction tube (containing the Binding Matrix and the sample) was inverted 
by hand for two minutes to allow the binding of the DNA to the matrix. The tubes were 
placed in a rack for seven minutes until the silica matrix had settled. 1.5 ml of the supernatant 
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were discarded. The matrix was resuspended in the remaining liquid, transferred to a SPINTM 
Filter and centrifuged at 13.000 rpm for one minute. The Filter was placed onto a new tube 
(the catch tube was discarded) and 500 µl SEWS-M were added to resuspend and wash the 
pellet followed by a centrifugation step of 13.000 rpm for one minute. After emptying the 
catch tube the SEWS-M and the centrifugation step were repeated. To dry the matrix another 
centrifugation step at 13.000 rpm for two minutes was performed. The SPINTM Filter was put 
into a new 1.5 ml reaction tube and air dried at room temperature for seven minutes. For the 
first elution 80 µl DES (DNAse/Pyrogen-Free Water) were pipetted onto the matrix, 
incubated for 15 minutes and centrifuged at 13.000 rpm for one minute. For the second 
elution 20 µl DES were pipetted onto the Filter and (without incubation) centrifuged at 13.000 
rpm for one minute. The SPINTM Filter was discarded and the DNA within the tube was 
stored at -20°C. 
For the DNA purification the same kit was used. 50 µl of the DNA were mixed with 489 µl 
sodium phosphate buffer, 61 µl MT buffer and 125 µl PPS in a 2 ml reaction tube by inverting 
ten times by hand. 500 µl of the resuspended Binding Matrix were added and mixed for two 
minutes. After settling of the matrix (approx. seven minutes) 650 µl of the supernatant were 
discarded and the matrix was resuspended in the remaining liquid and transferred onto a 
SPINTM Filter. The SPINTM Filter was centrifuged for one minute at 13.000 rpm. After 
emptying the catch tube 250 µl SEWS-M are pipetted onto the filter and the filter containing 
tube was centrifuged at 13.000 rpm for one minute and afterwards dried at 13.000 rpm for two 
minutes. The SPINTM Filter was placed onto a new 1.5 ml tube and air dried for seven 
minutes. The following two elution steps were performed as described above. 
2.2.1.2 Amplification of the V1-V4 region of the 16S rRNA gene from stool samples 
To target the variable regions V1 to V4 of the 16S rRNA gene a fragment of around 800 base 
pairs (bp) was amplified from each stool sample with the universal primers TPU1 and 805R 
(Table 2-3). Table 2-5 shows the composition of a standard PCR reaction with an end volume 
of 50 µl. 
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Table 2-5: Composition of a standard PCR reaction for the amplification of the V1-V4 region of the 16S 
rRNA gene from stool samples. 
Components Volume/Reaction Final Concentration 
Nuclease-Free Water 39.8 µl  
10x PCR Buffer (15 mM) 5 µl 1 x (1.5 mM MgCl2) 
MgCl2 (25 mM) 2 µl 1 mM 
Forward Primer TPU1 (10 µM) 0.5 µl 0.1 µM 
Reverse Primer 805R (10 µM) 0.5 µl 0.1 µM 
dNTPs  1 µl 200 µM of each 
Taq DNA Polymerase (5 U/µl) 0.2 µl 1 U (0.02 U/ µl) 
Template DNA 1 µl  
Final volume 50 µl  
 
The reagents were purchased from Qiagen, Peqlab (dNTPs) and Metabion (primers). The 
PCR program is described in Table 2-6. 
95°C 5 min  
95°C 30 sec  
55°C 30 sec 30 cycles
72°C 1 min  
72°C 10 min  
 
The PCR products were analyzed on a 1.5 % agarose gel to ascertain the correct amplicon size 
(about 800 bp, verified with the 100 bp Gene Ruler (Fermentas)). The amplicons were then 
ligated and transformed into competent E. coli cells. 
2.2.1.3 Ligation of the amplified V1-V4 region into the pCR® 2.1 vector 
The pCR® 2.1 TOPO TA Cloning® Kit (Invitrogen) was used for the ligation of the amplified 
800 bp fragments and the subsequent transformation into competent E. coli cells. The 
employed taq polymerase has a nontemplate-dependent activity that adds a single 
deoxyadenosin (A) to the 3´ends of the PCR products. The linearized vector supplied in the 
kit has single 3´deoxythymidine (T) residues thereby allowing the PCR inserts to ligate 
efficiently with the vector. 
Table 2-6: PCR program for the amplification of the V1-V4 region of the 16S rRNA gene from stool samples. 
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Table 2-7: Ligation reaction mix. 
Component Volume/Reaction Final Concentration 
Sterile Water 4 µl  
10 x Ligation Buffer 1 µl 1 x 
pCR® 2.1 vector (25 ng/µl) 2 µl 5 ng/µl 
T4 DNA Ligase (4 U/µl) 1 µl 4 U (0.4 U/µl) 
Fresh PCR product 2 µl  
Final volume 10 µl  
 
All components were pipetted into a pre-cooled Eppendorf tube, mixed gently and incubated 
at 14°C overnight. 
2.2.1.4 Transformation into competent E. coli cells and subsequent growing of clones 
One 50 µl vial of frozen competent E.coli cells was thawed on ice. Two µl of the ligation 
reaction were pipetted directly into the vial, mixed and incubated on ice for 30 minutes. A 
heat shock was performed for 30 seconds at 42°C and the vial was immediately placed back 
on ice for two minutes. 200 µl pre-warmed (37°C) SOC-Medium (Invitrogen) were added and 
the vial was stirred in a shaking incubator at 37°C at 350 rpm for one hour. 60 µl of the 
bacteria-SOC-mixture were spread on ampicillin-containing (50 µl/ml LB media) X-gal-
coated (40 µl/plate) LB agar plates and incubated at 37°C overnight. Three plates were 
prepared for each sample. To allow a proper blue-white staining the plates were stored at 4°C 
for one additional day. 
The technique of blue-white screening is based on a gap within the lacZ gene with the lacZ 
gene coding for the n-terminal α fragment of the β-galactosidase. The multiple cloning site of 
the pCR® 2.1 vector is located within the lacZα gene. Therefore successful ligation disrupts 
the lacZα gene and no functional β-galactosidase can be formed resulting in white colonies 
after incubation with X-gal. Colonies without insert express the α fragment and color blue. 
200 µl of the liquid LB media containing ampicillin (50 µl/ml LB) were pipetted into each 
well of a deep-well-plate. For each sample 192 white colonies were picked from the agar 
plates with an autoclaved toothpick and put into the LB containing wells. The plates were 
sealed and the colonies were allowed to grow at 37°C in a shaking incubator overnight. 
LB-medium was produced by dissolving 12.5 g LB-Medium (Luria/Miller (Roth) and 7.5 g 
DifcoTM Agar Noble (BD) in 500 ml aqua dest. The medium was autoclaved and stored at 
4°C. For plate pouring the medium was liquefied, ampicillin (50 µl/ml LB media) was added 
  2 MATERIAL AND METHODS 
19 
to the hand-warm medium and the plates were poured into petri dishes. After hardening, they 
were coated with X-gal (40 µl/plate). X-gal consists of 40 mg X-gal (Fermentas) per one ml 
dimethylformamide. For the preparation of liquid LB medium 12.5 g LB-Medium 
(Luria/Miller (Roth)) were dissolved in 500 ml aqua dest.. After autoclaving it was stored at 
4°C. Before use the medium was mixed with ampicillin at a concentration of 50 µl/ml LB. In 
general ampicillin was prepared by solubilizing 0.2 g ampicillin (Sigma-Aldrich) in one ml 
nuclease-free water. 
2.2.1.5 Colony PCR 
To check for the correct insert size a colony PCR was performed. Inserts were amplified using 
the vector specific primers M13(16)F and M13(17)R in a final volume of 50 µl. After the 
denaturation of 2.5 µl of the overnight grown bacteria (per well) at 95°C for ten minutes the 
PCR mix described in table 2-6 was simply added to the 96 well-format plates. 
Component Volume/Reaction Final Concentration
Nuclease-Free Water 40.35 µl  
10 x Dream TaqTM Buffer (20 mM MgCl2) 5 µl 1 x (2 mM MgCl2) 
Forward Primer M13(16)F (10 µM) 0.5 µl 0.1 µM 
Reverse Primer M13(17)R (10 µM) 0.5 µl 0.1 µM 
dNTPs 1 µl 200 µM of each 
Dream TaqTM DNA Polymerase (5 U/ µl) 0.15 µl 0.75 U (0.015 U/ µl) 
Denaturated Bacteria 2.5 µl  
Final volume 50 µl  
 
The reagents were purchased from Fermentas, Peqlab (dNTPs) and Metabion (primers). 
95°C 10 min  
95°C 1 min  
52°C 30 sec 32 cycles 
72°C 1 min  
72°C 10 min  
 
The PCR products were analyzed on a 1.5 % agarose gel to ascertain the correct amplicon size 
(about 970 bp, verified with the 100 bp Gene Ruler (Fermentas)). 
Table 2-8: Composition of the M13-colony-PCR reaction. 
Table 2-9: PCR program for the M13-colony-PCR reaction. 
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2.2.1.6 PCR product purification for the sequencing according to the method of Sanger 
For Sanger sequencing the PCR products underwent a purification step with an ExoI-SAP 
mixture. The exonuclease I (Exo I) (Fermentas) removes single stranded DNA and primer, the 
shrimp alkaline phosphatase (SAP) (Fermentas) hydrolyses remaining dNTPs. For one 
reaction 5.625 µl water were mixed with 0.3 µl SAP and 0.075 µl Exo I. Four µl of the M13-
colony-PCR product were added for the final volume of 10 µl and placed into a 37 °C thermo 
cycler for 15 minutes. With the subsequent incubation at 72 °C for 15 minutes the enzymes 
ExoI and SAP were inactivated. 
2.2.1.7 Sequencing according to the method of Sanger 
The sequencing was performed with the chain termination method according to Frederick 
Sanger as described in 1.6. (Sanger et al. 1977). 
The composition of the sequencing reaction is described in Table 2-10, the PCR program in 
Table 2-11. 
Component Volume/Reaction Endconcentration
Sterile water 4.8 µl  
5x BigDye® Terminator v1.1 Sequencing Buffer 1.85 µl 0.93x 
BigDye® Terminator v1.1 Ready Reaction mix 0.35 µl  
Primer TPU1 (3.2 µM ) 1 µl 0.32 µM 
Purified PCR product 2 µl  
Final volume 10 µl  
 
96°C 1 min  
96°C 10 sec  
50°C 5 sec 25 cycles 
60°C 4 min  
 
For the sequencing reaction the ABI PRISM® BigDye® Terminator v1.1 Cycle Sequencing 
Kit (Applied Biosystems) was used, with the BigDye® Terminator v1.1 Ready Reaction mix 
containing the dNTPs, the different labeled ddNTPs and the polymerase. The sequencing 
reaction product had to be purified of not-incorporated ddNTPs before the electrophoretic 
separation. Therefore SephadexTM G-50 Superfine (GE Healthcare) containing columns were 
Table 2-10: Composition of the sequencing PCR reaction according to the method of Sanger. 
Table 2-11: PCR program for the sequencing reaction according to the method of Sanger. 
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used. The ddNTPs were absorbed by the SephadexTM matrix, whereas the DNA passed the 
columns and was purified concomitantly. The eluate was then sequenced on a 3730xl DNA 
Analyzer (Applied Biosystems). 
2.2.1.8 Analysis of the 16S rRNA gene sequences generated by the method of Sanger 
The sequences were analyzed with the program MOTHUR version v.1.21.0 if not stated 
otherwise (Schloss et al. 2009). The sequences were aligned and screened for a minimum 
length of 700 bp and a maximum of seven homopolymers. The start and end points of the 
sequences were trimmed to range from position 43 to 754 (E.coli reference) and therefore 
encompass the variable regions V1 to V4. The sequences were further checked for possible 
chimeras with the chimera uchime command implemented in MOTHUR. Sequences that did 
not fulfill the given criteria or were detected to be chimerical, were excluded. 
For a first overview of the present phyla the sequences were classified according to the 
reference sequences of the Ribosomal Database Project (RDP) (Wang et al. 2009; Cole et al. 
2008). The identification of the microbial profiles on a finer taxonomic level was performed 
with an OTU-based analysis (operational taxonomic unit). For the OTU-based analysis a 
distance matrix was created by calculating uncorrected pair-wise distances between the 
aligned sequences. The cluster command using the average neighbor method (MOTHUR) was 
then performed to assign the sequences into OTUs (Schloss and Westcott 2011). The cutoff 
was set to 0.03, therefore clustering sequences showing at least 97% similarity into the same 
OTU, which indicates species level. A cutoff of 0.05 indicates genus level, whereas family 
level is indicated by a cutoff of 0.10. The OTU assignment was the basis for the subsequent 
analysis of the diversity and the identification of microbial profiles. The diversity, which is 
the variation, can be subdivided into α-diversity and β-diversity (Whittaker 1972). 
The α-diversity refers to diversity within a particular sample. Therefore the Good´s coverage 
estimation (Good 1953) was calculated. The coverage is defined as [1 - (n/N)] x 100, where n 
is the number of singleton sequences (OTUs with only one sequence) and N is the total 
number of sequences within the analyzed clone library. In addition the rarefaction curves 
were plotted showing the function of the number of species found to the clones that have been 
picked and sequenced. A steep increase and therefore also a low coverage indicates that a 
large amount of species are undetected and could be discovered by further sampling, whereas 
a smoother curve and therefore also a higher coverage indicates for appropriate sampling. 
With regard to richness, which is expressed as the number of species and is therefore just the 
simple count of the species found, the number of observed OTUs as well as the Chao1 species 
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richness were calculated (Chao 1984). The Chao1 species richness is an estimate of how 
many different sequences would be identified, if no more species would be found by further 
sampling. The equation therefore takes into account the observed number of species (which is 
the observed number of OTUs), the number of singletons (OTUs with only one sequence) and 
the number of doubletons (OTUs with only two sequences). Apart from richness, evenness 
quantifies how consistent the abundance of the species is. Richness combined with evenness 
results in diversity. The Shannon diversity H´ is calculated taking into account the number of 
species/sequences in OTUi and the total number of species/sequences within the 
community/all OTUs (Magurran 1988; Shannon 1948). 
The β-diversity refers to the diversity between the samples. Based on the OTU assignment the 
unweighted and weighted sample-wise Bray-Curtis index was calculated with the R package 
vegan. The unweighted index is a qualitative measurement and compares the community 
composition regarding presence and absence of the data, whereas the weighted index is a 
quantitative measure and takes into account the relative abundance of each species. The Bray-
Curtis index (BC) is a common metric that describes the dissimilarity between two 
communities and compares them in terms of the minimum abundance of each species/OTU. 
The exact formula is defined by one minus twice the sum of the minimum number of 
individuals in the ith OTU of community A and B divided by the sum of the number of 
individuals in the ith OTU of community A and community B [DBray-Curtis = 1 - 2*( min (SA,i, 
SB,i)) /  SA,i +  SB,i)]. The Bray-Curtis index is directly linked to the Sørensen similarity 
index (QS) and is one minus the Sørensen index (BC = 1-QS) between the same two 
communities. The Bray-Curtis index ranges between 0 and 1, where 0 indicates the two 
communities having the same composition and 1 that they do not share any species (Legendre 
& Legendre 1998; Bray & Curtis, 1957). Based on the unweighted as well as the weighted 
Bray-Curtis indices the MOTHUR-implemented PCoA command (Principal Coordinate 
Analysis) turned the indices into points in a space with a number of dimensions one less than 
the number of samples. The data points were visualized in a biplot using R. Possible 
significant differences between the clusters representing the different timepoints/treatments 
were tested with an AMOVA (2.2.1.9). To reduce the dataset and to take into account only the 
most abundant OTUs a SIMPER (similarity percentage) analysis implemented in the program 
PAST was conducted (Hammer et al. 2001). The SIMPER analysis is a simple method to 
assess which OTUs are primarily responsible for an observed difference between groups of 
samples (Clarke 1993). OTUs that contributed at least 0.5% to the overall similarity were 
included in the subsequent analyses. Based on the reduced dataset a Spearman correlation was 
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performed using R to identify OTUs that are responsible for the clustering of the timepoints 
and treatment groups. Further the Spearman correlation was performed on the taxon level, in 
which all OTUs representing the same genus were treated as one group. All correlated OTUs 
and taxa were plotted into the proper biplots. Another approach to check for responsible 
OTUs explaining differences between treatment groups and timepoints is the metastats 
approach and the search for indicator species. The same SIMPER-reduced datasets were used 
for the metastats approach as well as for the search for indicator species. The metastats 
approach compares the mean proportion and the variance of the OTUs between two 
environments (here: timepoint/treatment) (White et al. 2009). The indicator species defines a 
trait which is characteristic for the difference of two investigated environments (here: 
timepoints or treatments). In contrast to the metastats approach it not only compares the mean 
and the variance of the OTUs, but also the patterns of distribution of the OTUs found in the 
environment. Since the indicator species approach is a permutation model, 104 permutations 
were conducted (Dufrêne and Legendre 1997). 
The final classification of the OTUs and taxa was performed with a BLAST against the 
reference sequences of the Ribosomal Database Project (RDP), which is implemented in 
MOTHUR (Cole et al. 2009). The classification on species level was conducted with a 
BLAST against the 16S ribosomal RNA sequences database of the NCBI (National Center for 
Biotechnology Information). 
2.2.1.9 Statistical analysis 
To test for significant differences in the richness and diversity indices the R package 
exactRankTests was used. The significance of differences between the timepoints "Day 0" 
and "Day 4" was calculated with the paired Wilcoxon signed rank test (Wilcoxon 1945). To 
check for an influence of the probiotic in comparison to the placebo the timepoint "Day 46" 
was set as the most important timepoint and displays the central question of the study. Due to 
the fact that for the analysis of the mucosa-associated microbiota this "Day 46" was the only 
timepoint at which samples had been taken during the probiotic and placebo therapy, the 
differences between the therapies at the "Day 14" and "Day 28" within the analysis of the 
luminal microbiota were seen as less important intermediate timepoints. For the analysis of 
the influence of the probiotic the difference between the timepoints "Day 0" and "Day 46" 
was calculated and the subsequent unpaired Wilcoxon rank sum test (also called Mann-
Whitney U) was used to test the placebo against the probiotic group (Mann and Whitney 
1947). The same procedure was used for the timepoints "Day 14" and "Day 28", but those 
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values had not to be corrected for multiple testing due to the fact that this was a secondary 
approach. The appropriate randomization into the later placebo and probiotic group was 
checked by calculating the difference between the timepoints "Day 0" and "Day 4" and to test 
the later placebo group against the later probiotic group with the Wilcoxon rank sum test. To 
check for resilience the timepoints "Day 14", "Day 28" an "Day 46" were compared to the 
"Day 0" by the Wilcoxon signed rank test. All results of the statistical tests were corrected for 
multiple testing by the Bonferroni-Holm correction (Holm 1979). P values less than 0.05 after 
Bonferroni-Holm correction indicated a significant difference between the two tested groups. 
To test if the samples cluster together according to the timepoint or treatment and if clusters 
are significantly separated from each other as supposed by the PCoA an analysis of molecular 
variance (AMOVA) was performed by using the Bray-Curtis indices. The AMOVA in general 
is the non-parametric analog of the analysis of variance and tests whether the centers of the 
clusters representing the different treatment groups or timepoints are more separated than the 
variance among the samples within a cluster. For each AMOVA 104 permutations were 
performed. The resulting p-values were corrected for multiple testing due to the Bonferroni-
Holm correction. A corrected p-value below 0.05 was considered significant. 
2.2.2 16S rRNA and 16S rRNA gene libraries from biopsy samples 
For each individual three biopsies from the sigmoid colon had been collected via 
sigmoidoscopy. The first at the beginning of the study (day 0), the second after the three days 
of antibiotic treatment (day 4) and the last at the end of the study (day 46). The bacterial 16S 
rRNA gene encompassing the variable regions one and two (V1-V2) was amplified and 
sequenced with the pyrosequencing 454 technology. 
2.2.2.1 Extraction of DNA and RNA from biopsy samples 
The extraction of DNA and RNA from the biopsy samples was performed with the AllPrep 
DNA/RNA Mini Kit (Qiagen). The biopsies had been stored at -80°C and the first steps of the 
extraction were performed in liquid nitrogen. The biopsy was transferred into a pre-cooled 
reaction tube (Eppendorf) and squashed with a pestle. 600 µl of the RLT-buffer/β-
Mercaptoethanol mixture (1 µl β-Mercaptoethanol per 100 µl RLT-buffer) were added. After 
the biopsy was thawed it was filled into a Lysing Matrix E tube (MP Biomedicals) and 
homogenized in a FastPrep FP 120 (Bio 101) at speed 4 for 45 seconds twice. After the 
incubation for two hours at room temperature, the tube was centrifuged at 13.000 rpm for 30 
seconds. The supernatant was transferred into a QIAshredderTM column and centrifuged at 
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13.000 rpm for two minutes. The supernatant was pipetted into the AllPrep DNA Mini Spin 
Column and the column was centrifuged at 10.000 rpm for 30 seconds. The collection tube 
contained the RNA, while the filter contained the DNA and was placed onto a new 2 ml 
collection tube and temporarily stored at 4°C. 
600 µl of 70% ethanol (Sigma-Aldrich) were pipetted into the collection tube containing the 
RNA and gently mixed with the pipette tip. The RNA/ethanol solution was transferred into a 
RNeasy Mini Spin Column and centrifuged at 10.000 rpm for 15 seconds. The flow-through 
was discarded and the step repeated with the remaining RNA-ethanol solution. 350 µl of RW1 
buffer were pipetted onto the column and centrifuged at 10.000 rpm for 15 seconds. The flow-
through was discarded. 80 µl of the DNAse-Incubation-Mix (70 µl RDD buffer + 10 µl 
DNAse Solution) were pipetted onto the column membrane and incubated for 15 minutes at 
room temperature. 350 µl RW1 buffer were added and the column was centrifuged at 10.000 
rpm for 15 seconds. The flow-through was discarded. 500 µl RPE were added and centrifuged 
at 10.000 rpm for 15 seconds, the flow-through was discarded. 500 µl RPE were pipetted a 
second time and centrifuged at 10.000 rpm for two minutes. The flow-through was discarded 
and the column centrifuged an additional time at 13.000 rpm for one minute. The collection 
tube was discarded and the column placed into a RNAse-free 1.5 ml reaction tube. 50 µl 
RNAse-free water were added and incubated at room temperature for five minutes. The tube 
was centrifuged at 10.000 rpm for one minute. The reaction tube now contained the RNA and 
was stored at -80°C. 
500 µl of buffer AW1 were added to the temporarily stored collection tube containing the 
DNA and centrifuged at 10.000 rpm for 15 seconds. The flow-through was discarded. 500 µl 
buffer AW2 were pipetted onto the column and centrifuged at 13.000 rpm for two minutes. 
The flow-through was again discarded. The column was placed onto an new 1.5 ml reaction 
tube, 100 µl EB-buffer were directly pipetted onto the membrane and incubated at room 
temperature for one minute. The tube was centrifuged at 10.000 rpm for one minute and the 
solution within the tube was once again eluted via the column. The reaction tube was 
centrifuged at 10.000 rpm for one minute, contained the DNA then and was stored at -20°C. 
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2.2.2.2 Reverse Transcription of RNA 
The extracted RNA had to be reverse transcribed into cDNA. This was done with the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The composition of the 
PCR reaction can be looked up in Table 2-12. 
Component Volume/Reaction Endconcentration
RT-PCR Grade Water 3.2 µl  
10x RT Buffer 2.0 µl 1x 
10x RT Random Primers 2.0 µl 1x 
25x dNTP Mix (100 mM) 0.8 µl 1x (4 mM) 
MultiScribeTM Reverse Transcriptase (50 U/µl) 1.0 µl 50 U (2.5 U/µl) 
RNAse Inhibitor (20 U/µl) 1.0 µl 20 U (1 U/µl) 
RNA template 10 µl  
Final volume 20 µl  
 
The program for the reverse transcription PCR was ten minutes at 25°C followed by 120 
minutes at 37°C and five seconds at 85°C. 
2.2.2.3 Amplification of the V1-V2 region of the 16S rRNA and the 16S rRNA gene 
from biopsy samples 
The pyrosequencing approach targeted the V1 and V2 region. Therefore specific primers were 
used (see Table 2-1). The Pyro_27F primer (5´- CTA TGC GCC TTG CCA GCC CGC TCA 
GTC AGA GTT TGA TCC TGG CTC AG -3´) consists of the B-Adaptor (underlined) and the 
universal primer 8F (italic). The MIDX_338R primers (5´- CGT ATC GCC TCC CTC GCG 
CCA TCAG NNNNNNNNNN CA TGC TGC CTC CCG TAG GAG T -3´) comprises the A-
Adaptor (underlined), a unique 10-base barcode (N) and the broad range bacterial 338R 
primer (italic). Due to 50 different barcodes (and therefore 50 different reverse primers (see 
Table 2-3)) it was possible to pool up to 50 different samples into the same library (see 
2.2.2.4). Each sample was amplified in a final volume of 25 µl in duplicate. To be sure of 




Table 2-12: Composition of the reverse transcription PCR reaction. 
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Component Volume/Reaction Endconcentration 
RT-PCR Grade Water ad 25 µl  
5x Phusion® HF Reaction Buffer (7.5 mM MgCl2) 5.0 µl 1x (1.5 mM MgCl2)
Pyro_27F (10 µM) 0.5 µl 0.2 µM 
dNTPs 0.5 µl 200 µM of each 
Phusion® Hot Start II DNA Polymerase (2 U/µl) 0.25 µl 0.5 U (0.02 U/µl) 
MIDX-338R (10 µM) 0.5 µl 0.2 µM 
DNA/cDNA template 2-4 µl  
Final volume 25 µl  
 
Buffer and polymerase were contained in the Phusion® Hot Start DNA Polymerase Kit from 
ThermoFisher Scientific. The other reagents were purchased from Peqlab (dNTPs) and 
Metabion (primers). 
98°C 3 min  
98°C 10 sec  
57°C 30 sec 30 cycles 
72°C 30 sec  
72°C 10 min  
 
The replicate PCR products were pooled and loaded on a 2% agarose gel. After an 
electrophoresis at 100V for 75 min, the band with the size of about 420 bp (verified with the 
100 bp Gene Ruler (Fermentas)) was cut with a gel excision tip (Biostep) under UV light and 
transferred into a 1.5 ml reaction tube for further gel extraction. 
2.2.2.4 Gel extraction and pooling of amplicons 
For the gel extraction the Min Elute® Gel Extraction Kit (Qiagen) was used. 200 µl of buffer 
QG were added to the cut band and incubated at 50°C for ten minutes. For a better dissolution 
of the band the tube was vortexed every 2-3 minutes during the incubation. 68 µl 2-Propanol 
(Sigma-Aldrich) were added to the sample and mixed by inverting several times. The liquid 
was transferred into a MinElute column and centrifuged at 13.000 rpm for one minute. The 
flow-through was discarded, 500 µl buffer QG were added and the tube centrifuged again at 
13.000 rpm for one minute. A washing step was performed with 750 µl buffer PE followed by 
a subsequent centrifugation at 13.000 rpm for one minute. The flow-through was discarded 
Table 2-13: Composition of a standard PCR reaction for the amplification of the V1-V2 region of the 
16S rRNA gene and the 16S rRNA from biopsy samples. 
Table 2-14: PCR-program for the amplification of the V1-V2 region of the 16S rRNA gene and the 
16S rRNA from biopsy samples. 
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and the tube centrifuged for an additional minute. The MinElute column was placed into a 
new 1.5 ml reaction tube. For the elution 10 µl buffer EB were directly pipetted on to the filter 
membrane. After an incubation for one minute, the tube was centrifuged for one minute. 
Again 10 µl of buffer EB were added, incubated for one minute and centrifuged at 13.000 rpm 
for one minute. The extracted DNA/cDNA was contained within the tube. The concentration 
of DNA and cDNA was measured with the Qubit® ds DNA BR Assay Kit (Invitrogen) with a 
Qubit® 2.0 Fluorometer. Equal concentrations of the samples/amplicons containing different 
MIDs were pooled into one library. Each library was sequenced on a quarter slide with the 
454 GS FLX (Roche) according to the recommended procedures of Roche. 
2.2.2.5 Pyrosequencing with the GS FLX according to Roche 
In comparison to the Sanger sequencing the pyrosequencing observes the DNA polymerase in 
action where one after the other nucleotide is incorporated into the newly synthesized DNA 
strand. The successful integration of a nucleotide is recognized via an enzyme system and a 
luciferase converted into light which is recognized by a detector. If the nucleotide does not fit 
there is no light. 
For the generation of amplicon libraries PCR products were created by amplifying the 
template with specific fusion primers containing the 454 sequencing adaptor sequences as 
described in chapter 2.2.2.3. The adaptors were used for the subsequent purification, 
quantitation, amplification and sequencing steps. The single-stranded libraries were 
immobilized onto specifically designed DNA Capture Beads with each bead carrying a unique 
single-stranded library fragment. The beads were than emulsified with amplification reagents 
in a water-in-oil mixture mimicking microreactors containing just one bead with one unique 
sample-library fragment. The entire emulsions were than amplified in their microreactors in 
parallel to create millions of clonally copies of each library fragment on each bead. 
Subsequently the emulsions were broken while the amplified fragments remained bound to 
their specific beads. The fragments were enriched and the beads were loaded onto a 
PicoTiterPlate device, whereas the surface design allowed for only one bead per well. The 
PTP Device was then sequenced in the GS FLX (Roche). Individual nucleotides were flowed 
in a fixed order across the thousands of wells, each containing one bead. Each incorporation 
of one (or more) nucleotide(s) complementary to the template strand resulted in a detectable 
light signal which was recorded by the CCD camera within the instrument, with the signal 
strength being proportional to the number of nucleotides incorporated in a single nucleotide 
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flow. The 454 Sequencing Data Analysis software used the signal intensity of each 
incorporation event at each well position to determine the sequence of all reads in parallel. 
2.2.2.6 Analysis of the 16S rRNA and the 16S rRNA gene sequences generated by 
pyrosequencing 
The resulting sequence- and quality file containing all reads and Phred quality scores of a 
quarter slide were checked and sequences with a length of less than 200 bp and a minimum 
mean Phred quality score of 25 were discarded by utilizing the Perl-based software PANGEA 
(pipeline for analysis of next generation amplicons (Giongo et al. 2010)). The remaining 
sequences were split according to their sample-barcode using PANGEA as well. Samples with 
less than 2000 sequences were eliminated and repeated. The remaining sequences were 
denoised by eliminating sequences with ambiguous bases, with more than one difference to 
the primer sequence, more than seven homopolymers, a length less than 200 bp and sequences 
being chimerical using the software MOTHUR version v.1.21.0 (Schloss et al. 2009). Further 
the sequences were adjusted concerning the start and end point of the sequences ranging from 
position 43 to 337 (E.coli reference) and therefore covering the V1 and V2 region. To get rid 
of the uneven distribution of the sequence amount all samples were normalized to the lowest 
number of sequences. 
The subsequent analyses were performed as described for the sanger-sequenced data. Again a 
first superficial classification and subsequent OTU-based analysis were performed (see 
2.2.1.8). 
2.2.2.7 Statistical analysis 
Statistical significant differences within the different α-diversity indices were identified with 
the Wilcoxon signed rank test (paired samples) and the Wilcoxon rank sum test (unpaired 
samples) by using the exactRankTest package implemented in R. For the statistical analysis of 
the β-diversity an AMOVA (MOTHUR) was conducted. The Bonferroni-Holm correction 
was assessed to adjust for multiple testing (see 2.2.1.9) (Holm 1979). 
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2.2.3 Quantitative real-time PCR for quantitative results of bacteria 
To receive additional information on the quantitative abundances of the total bacteria, the 
Firmicutes and the Bacteroidetes within the luminal as well as in the mucosa-associated 
microbiota a quantitative real-time PCR was performed with beta actin functioning as 
housekeeping gene. For the real-time PCR approach the Power SYBR® Green PCR Master 
Mix (Applied Biosystems) was used. 4.5 µl of the master mix were prepared with 0.0625 µl 
template (luminal DNA or mucosa-associated DNA or reverse transcribed RNA (see 2.2.1.1, 
2.2.2.1 and 2.2.2.2), 0.125 µl of the forward and the reverse primer (10 µM each) and RT-
PCR Grade Water to a final volume of 10 µl. Each sample was analysed in triplicate. The 
PCR program was as described in Table 2-15. 
50°C 2 min  
95°C 10 min  
95°C 15 sec 45 cycles (luminal samples) 
60°C 1 min 50 cycles (fecal samples) 
95°C 15 sec  
60°C 15 sec establishes the melting curve 
95°C 15 sec  
 
The results were obtained with the 7900HT Fast Real-Time PCR System (Applied 
Biosystems) and visualized with the software SDS 2.3 (Applied Biosystems). 
2.2.3.1 Analysis of quantitative real-time results 
The resulting cycle thresholds (Ct) were converted into a linear signal by calculating 2-Ct. The 
median of the triplicates was used for the further analysis. Each sample was normalised to the 
beta actin value by calculating the ratio of the median 2-Ct of the target to the median 2-Ct of 
the respective beta-actin. The values of Firmicutes and Bacteroidetes could then be further set 
into relation to the values of the total bacteria. Differences between timepoints and treatments 
were calculated by using the Wilcoxon signed rank test (paired samples) and the Wilcoxon 
rank sum test (unpaired samples) with the exact RankTest package implemented in R as 
already described in 2.2.1.9 and 2.2.2.7). The correction for multiple testing was performed 
by the Bonferroni-Holm method (Holm 1979). 
Table 2-15: PCR program of the quantitative real-time PCR. 
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3 Results 
3.1 16S rRNA gene clone libraries from luminal samples 
For the generation of the clone libraries, the V1-V4 region of the 16S rRNA gene from stool 
(luminal) samples were amplified, ligated into the pCR® 2.1 vector and transformed into 
competent E. coli cells. 192 clones from each sample were picked, checked for the correct 
insert size and finally sequenced according to the method of Sanger. 
The resulting 19.200 sequences (100 samples (20 individuals at five different timepoints) with 
192 picked clones each) were cleaned by eliminating bad quality sequences (length less than 
700 bp, more than seven homopolymers) as well as chimerical sequences with the program 
MOTHUR v.1.21.0 (Schloss et al. 2009). 3.292 sequences (17%) had to be discarded, 
resulting in a denoised final data set of 15.908 sequences for further analysis. 
For the analysis, a first classification was performed to receive an overview of the involved 
phyla and the overall influence of the antibiotic and the subsequent probiotic or placebo 
therapy. In addition, an OTU-based analysis was performed. This approach assigns the 
sequences into "groups", the so-called Operational Taxonomic Units (OTUs), based on a 
threshold of 0.03. Therefore OTUs with a least 97% identity are assigned into the same OTU. 
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3.1.1 First classification of the denoised dataset of the luminal microbiota 
A classification with the Ribosomal Database Project (RDP) (Cole et al. 2009) gave a first 
impression of the involved phyla. Figure 3-1 shows the percentages of the five phyla found 
within the fecal samples at timepoint "Day 0". These are in descending occurrence: 
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and others which encompass 
Verrucomicrobia and unclassified bacteria. This is a common picture of the phyla distribution 
of healthy individuals. 
Figure 3-1: Phylum distribution of the luminal microbiota of the twenty healthy individuals at timepoint 
"Day 0". Described in percent. Sequences were generated by sequencing according to the method of Sanger. 
To obtain an overview of the influence of the antibiotic and the subsequent placebo as well as 
probiotic treatment onto the phylum distribution, the sequences of the other timepoints were 
also classified via RDP. The median and the quartiles of the two main phyla, Firmicutes and 
Bacteroidetes, of each treatment group/timepoint were calculated and plotted into boxplots. 
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Figure 3-2: Changes in the two main luminal phyla due to antibiotic treatment and subsequent placebo or
probiotic therapy. (A) Firmicutes. (B) Bacteroidetes. Median, upper and lower quartile as well as upper and
lower whisker are plotted. Grey (D0): Timepoint "Day 0" (n = 20), Red (D4): Timepoint "Day 4" after antibiotic
treatment (n = 20), blue (D46): Timepoint "Day 46" after placebo therapy (n = 10), green (D46VSL): Timepoint





For the Firmicutes (Figure 3-2 
(A)), which is the most 
abundant phylum in the 
luminal microbiota (nearly 
80%), there was a significant 
decrease (pcorr = 0.0031) down 
to 52% due to the antibiotic 
treatment. After allocation to 
placebo or probiotic 
Firmicutes recovered reaching 
nearly the initial amount at 
Day 46 (comparison of "Day 
0" and "Day 46", pcorr > 1). 
However, there is no 
significant difference between 
the placebo and the probiotic 
therapy at either of the three 
timepoints (“Day 14” and 
“Day 28” pcorr > 1 and “Day 
46” pcorr = 0.8704). For 
Bacteroidetes (Figure 3-2 (B)) 
the opposite trend could be 
seen. Due to the antibiotic 
treatment there was a 
significant increase  
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(pcorr = 0.0019) of Bacteroidetes from 10% to nearly 40%. The allocation to the placebo or the 
probiotic treatment resulted in a decrease. Again there were no significant differences 
between the placebo and the probiotically treated group at all the three timepoints (pcorr > 1). 
Furthermore there was no significant difference between the timepoints "Day 0"and "Day 46" 
(pcorr > 1), indicating a good recovery. 
Since the simple classification of the sequences will not give any more information regarding 
diversity and compositional changes of the microbiota an OTU-based analysis was performed. 
3.1.2 OTU-based analysis 
As a first step the cleaned 15.908 sequences within the final dataset were aligned by the 
Needleman-Wunsh algorithm. A distance matrix was then generated by calculating the 
uncorrected pair-wise distances between the aligned sequences. Based on the distances the 
sequences were assigned into OTUs with sequences having at least 97% similarity belonging 
to the same OTU, which corresponds to species level. Further the clustering was performed 
on the genus level, describing 95% identity. The clustering itself was based on the average 
neighbor method (for further details see chapter 2.2.1.8). The final dataset of 15.908 
sequences were grouped into 6.862 OTUs, which are the basis for the subsequent analysis. 
3.1.2.1 Alpha-Diversity 
Measures of alpha diversity were applied to evaluate the aspects of bacterial diversity that 
may be influenced by treatment or timepoint. The alpha diversity in general describes the 
species composition within a specific sample. 
The Good´s coverage estimation (Good 1953) is defined as [1 - (n/N)] x 100, where n is the 
number of singleton sequences and N is the total number of sequences within the analyzed 
clone library. It was very unequal in the investigated samples ranging between 4.19% to 
94.59 % (for individual data see Table 7.2 in the appendix). A low coverage indicates many 
singletons and a therefore incomplete sampling. The rarefaction curves (Figure 3-3) show this 
figuratively. The sample with the lowest coverage represents a very steep rarefaction curve 
(10_D0), whereas the sample with the best coverage represents a quite smooth rarefaction 
curve (19_D4). The rarefaction curve of the sample 14_D14 is characterized by a median 
coverage. 
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Figure 3-3: Rarefaction curves of the luminal samples of four individuals. Steep curves represent samples 
with a low coverage, whereas smoother curves represent a higher coverage. 
The low coverage as well as the steep rarefaction curve of several samples show that the 
number of 192 clones that had been picked for each sample is not sufficient to catch all the 
different bacteria inhabited in this sort of sample to present a complete microbial profile. 
Nevertheless, the data enable a first estimation of the microbial variety. Therefore different 
measures that focus on species richness and diversity have been calculated. 
Species richness in general is the number of different species in a given sample. Therefore the 
number of observed species as well as the Chao1 estimated richness was calculated. Based on 
the individual values (see Table 7.2 in the appendix) the means and the quartiles of the 
treatments and the timepoints were calculated and depicted as boxplots. The timepoints "Day 
0" and "Day 4" comprise 20 individuals. Due to the subsequent allocation to different 
treatment groups the timepoints "Day 14", "Day 28" and "Day 46" are comprised of ten 
individuals within the placebo as well as in the probiotic group. 
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As depicted in Figure 
3-4 the antibiotic 
treatment led to a 
significant decrease 
within the number of 
observed OTUs 
(Wilcoxon signed rank 
test: pcorr = 0.000504). 
The subsequent 
placebo as well as the 
probiotic therapy 
resulted in a 
regeneration. The 
central question was 
whether a significant 
difference between the 
placebo and the 
probiotic treatment at 
"Day 46" could be 
observed. That was not 
the case (Wilcoxon rank sum test: pcorr > 1). Also the differences between the placebo and the 
probiotic group at the timepoints "Day 14" (pcorr = 0.5508) and "Day 28" (pcorr > 1) were not 
significantly different. Since there was no significant difference between the placebo and the 
probiotic group at either of the timepoints, the placebo and the probiotic group of each 
timepoint were combined for the comparison to the initial timepoint "Day 0". For the 
comparison between Day 0 the particular timepoints "Day 14", "Day 28" and "Day 46" a 
Wilcoxon signed rank test was performed. All three comparisons were significant ("Day 14" 
pcorr = 0.0004082; "Day 28" pcorr = 0.00132 and "Day 46" pcorr = 0.02972), indicating that 
even after 43 days post antibiotic treatment the microbiota was not able to fully recover to the 
initial state of observed OTUs. To test for an appropriate randomization the differences of 
“Day 4” and “Day 0” were calculated and the later placebo and the later probiotic group were 
then compared with the Wilcoxon rank sum test. The result was not significant. Further no 
gender-dependent effects could be detected. 
Figure 3-4: Boxplots of the number of observed OTUs of the luminal
microbiota. Median, upper and lower quartile as well as upper and lower
whisker are plotted. Grey (D0): Timepoint "Day 0" (n = 20), Red (D4):
Timepoint "Day 4" after antibiotic treatment (n = 20), blue (D46): Timepoint
"Day 46" after placebo therapy (n = 10), green (D46VSL): Timepoint "Day 46"
after probiotic therapy (n = 10). * indicates significant differences after
Bonferroni-Holm correction compared to timepoint "D0". 
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In addition to the 
observed OTUs the 
Chao1 estimator of 
species richness (Chao 
1984) takes into 
account the number of 
OTUs with only one 
sequence ("singletons") 
and the number of 
OTUs with only two 
sequences ("double-
tons"). A significant 
decrease (pcorr = 
0.0441) in the Chao1 
richness could be 
observed due to the 
antibiotic therapy 
(Figure 3-5). The 
subsequent randomi- 
sation was appropriate 
(pcorr = 0.6842). The regeneration resulted in a steady increase of richness, with values being 
higher within the probiotic group at each of the timepoints. However, the differences between 
the placebo and the probiotic do not reach statistical significance at either of the timepoints 
(“Day 14” pcorr = 0.786; “Day 28” pcorr > 1 and “Day 46” pcorr = 0.369). The comparisons of 
the timepoints "Day 14", "Day 28" and "Day 46" to timepoint "Day 0" revealed no significant 
differences. Further there was no gender-dependent effect. 
Species diversity of a given sample is the number of different species in a particular sample 
weighted by the number of individuals belonging to a species (= species evenness). As shown 
before for the richness, diversity shows a decrease due to the antibiotic treatment (pcorr = 
0.00014) (Figure 3-6). The randomization afterwards was appropriate (pcorr = 0.22578). 
However, there was no difference between the placebo and the probiotic group in the 
subsequent resilience at the timepoints "Day 14" (pcorr = 0.786) , "Day 28" (pcorr > 1) and "Day 
46" (pcorr > 1). Further there were significant differences in the comparison of those 
Figure 3-5: Boxplots of the Chao1 species richness of the luminal microbiota.
Median, upper and lower quartile as well as upper and lower whisker are plotted.
Grey (D0): Timepoint "Day 0" (n = 20), Red (D4): Timepoint "Day 4" after
antibiotic treatment (n = 20), blue (D46): Timepoint "Day 46" after placebo
therapy (n = 10), green (D46VSL): Timepoint "Day 46" after probiotic therapy (n
= 10). * indicates significant differences after Bonferroni-Holm correction
compared to timepoint "D0". 
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timepoints and the 
initial diversity of 
timepoint "Day 0" 
("Day 14" pcorr = 5.7e-
06; "Day 28" pcorr = 
3.3e-04; "Day 46" pcorr 
= 0.0091). This 
indicates that the 
microbiota with regard 
to diversity is 
recovering and 
approximates to the 
initial composition 
during the time, but is 
finally not able to 
recover completely 
within the timeframe 
of the study. 
 
 
Concerning alpha diversity it can be summed up that due to the antibiotic treatment there is a 
significant decrease in microbial richness as well as in diversity. A regeneration of the 
microbiota after allocation to placebo or probiotics is obvious (richness as well as diversity 
index increase again), but the recovery does not reach the initial composition as indicated by 
significant differences between the timepoints "Day 0" and "Day 46". Therefore it can be 
concluded that resilience is incomplete. Furthermore, the resilience process is independent of 
the probiotic therapy as there are no significant differences between the placebo and the 
probiotic group at any timepoint. 
 
Figure 3-6: Boxplots of the Shannon H´ of the luminal microbiota. Median,
upper and lower quartile as well as upper and lower whisker are plotted. Grey
(D0): Timepoint "Day 0" (n = 19), Red (D4): Timepoint "Day 4" after antibiotic
treatment (n = 19), blue (D46): Timepoint "Day 46" after placebo therapy (n =
10), green (D46VSL): Timepoint "Day 46" after probiotic therapy (n = 9).
* statistically significant at a level of 0.05 after Bonferroni-Holm correction. 
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Figure 3-7: Biplot of unweighted Bray-Curtis indices of the luminal
microbiota. "Day 0" (n = 20) ...; "Day 4" (after antibiotic treatment; n =
20)....; probiotic treated group at "Day 14"....,"Day 28".....and "Day 46"....;
placebo treated group at "Day 14"...., "Day 28".....and "Day 46".....(n = 10
for all the remaining groups). 
3.1.2.2 Beta-diversity 
In general, beta diversity calculates the membership (presence/absence) and the structure 
(diversity) between the samples. Based on the OTU grouping the unweighted as well as the 
weighted Bray-Curtis indices were calculated for each sample-wise comparison with the R 
package vegan. The indices were transformed into data points by using a Principal Coordinate 
Analysis (PCoA) with three principal coordinates. This allows to look for the most important 
axes along which the samples vary and to find clusters. The results were plotted into a three-
dimensional biplot using R. 
Unweighted Bray-Curtis indices 
Unweighted beta-diversity is a qualitative measurement and takes into account the absence 
and the presence of an OTU. 
Figure 3-7 shows the biplot 
of unweighted Bray-Curtis 
indices of the fecal 
samples. Each dot 
represents one individual (n 
= 100). The grey circles 
represent all individuals at 
timepoint "Day 0" (n = 20), 
the red circles all 
individuals at "Day 4", 
after the antibiotic 
treatment (n = 20). The 
greenish circles represent 
those individuals that were 
administered probiotic 
treatment at the three 
timepoints "Day 14", "Day 
28" and "Day 46", whereas 
the bluish circles represent all placebo treated individuals (n = 10 per treatment group at one 
timepoint). The first principal coordinate (PCo 1), which separates out the data as much as 
possible, explains 3.47% of the variation of the samples. 
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To test if there are significant differences between the treatment groups and timepoints an 
AMOVA was performed. Table 3-1 shows the results of the AMOVA for the unweighted 
Bray-Curtis indices after correction for multiple testing. 
Table 3-1: Results of the AMOVA for unweighted Bray-Curtis indices of the luminal microbiota. 104 
permutations were performed. Values after Bonferroni-Holm correction for multiple testing (n = 28). Cells 




Day 4 Day 14 Day 28 Day 46 
Treatment Day 0 Antibiotic Placebo VSL#3 Placebo VSL#3 Placebo VSL#3
  Day 0   5.6e-04 0.0504 0.0145 1 0.0504 1 0.0315
Day 4 Antibiotic 0.1748 1 0.5280 0.5280 0.5941 0.5280
Day 14 Placebo 
0.0008 1 0.3249 1 0.0081
VSL#3 0.0300 1 0.0638 1 
Day 28 Placebo 
1 1 0.5280
VSL#3 1 1 
Day 46 Placebo 
0.3454
VSL#3   
 
The result of the AMOVA shows a significant difference between "Day 0" (grey circles) and 
the antibiotically treated group at "Day 4" (red circles), indicating a significant influence of 
the antibiotic onto the gut microbiota. Further there is a significant difference between the 
placebo and the probiotic group at timepoint "Day 14" (light blue circles compared to light 
green circles), but not at "Day 28" and “Day 48”. 
Since there are some significant differences shown within the AMOVA, it is interesting to see 
which OTUs were responsible for the clustering and the separation of the different treatment 
groups. For this purpose a SIMPER analysis was performed. Therefore only OTUs with a 
minimum contribution of 0.5% to the overall similarity have been taken into account for the 
subsequent Spearman correlation, correlating the OTUs to the axes of the biplot. Table 3-2 
shows the results of the Spearman correlation with OTUs fulfilling the false discovery rate 
(fdr) of 0.05. To give a hint in which direction the OTUs show, only those OTUs that 
survived the fdr of 0.0001 (as highlighted in grey within the Table 3-2), were plotted into the 
biplot in Figure 3-8. 
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Table 3-2: Statistical significant results of the Spearman correlation of OTUs and unweighted Bray-Curtis 
indices of the luminal microbiota. OTUs with a minimum contribution of 0.5% to the overall similarity. Fdr of 
0.05. Cells highlighted in grey: OTUs that are plotted into the biplot in Figure 3-8 fulfilling the fdr of 0.0001. 
OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
4 uncl. Lachnospiraceae -0.3277 -0.0363 -0.0880 0.3413 2.62e-03 5.70e-03 
7 Blautia -0.3300 -0.5369 0.0545 0.6326 2.55e-08 4.25e-07 
8 Blautia -0.4453 -0.0227 0.0423 0.4478 1.04e-05 6.47e-05 
13 Blautia -0.4913 -0.3903 0.0233 0.6279 6.32e-07 6.31e-06 
17 uncl. Lachnospiraceae -0.4996 0.2933 -0.4696 0.7458 3.64e-07 4.55e-06 
18 uncl. Lachnospiraceae -0.2930 0.4146 -0.3222 0.6013 5.39e-05 2.44e-04 
24 uncl. Lachnospiraceae -0.3614 0.1893 -0.3390 0.5305 6.61e-04 1.65e-03 
33 Faecalibacterium -0.3210 -0.0395 -0.1887 0.3745 3.38e-03 6.76e-03 
46 Blautia -0.4590 -0.2245 -0.1407 0.5300 4.68e-06 3.90e-05 
47 Akkermansia -0.1984 0.1400 -0.3297 0.4094 2.43e-03 5.58e-03 
69 Sporacetigenium -0.4480 0.0419 0.1597 0.4775 8.86e-06 6.33e-05 
80 Dialister -0.2106 -0.3157 -0.2262 0.4418 4.13e-03 7.94e-03 
81 Bacteroides -0.3294 0.0861 0.2495 0.4221 2.46e-03 5.58e-03 
91 Bacteroides -0.1172 0.3264 0.1165 0.3658 2.76e-03 5.75e-03 
173 Bacteroides -0.1768 0.1282 0.3942 0.4507 1.48e-04 5.75e-03 
182 Bacteroides 0.0288 0.0357 0.5485 0.5504 1.04e-08 2.60e-07 
247 Pseudomonas -0.2716 -0.1732 -0.1052 0.3389 1.88e-02 2.99e-02 
287 Bacteroides -0-0437 0-0532 -0-2710 0-2796 1-91e-02 2.99e-02 
330 Turicibacter -0.2543 0.4130 -0.1181 0.4992 5.86e-05 2.44e-04 
352 uncl. Peptostreptococcaceae -0.3751 0.1433 0.0905 0.4116 3.62e-04 1.00e-03 
369 Dorea -0.2684 0.1900 -0.2036 0.3868 2.08e-02 3.08e-02 
387 uncl. Lachnospiraceae  -0.2665 0.2314 0.0667 0.3592 2.21e-02 3.16e-02 
389 Dorea -0.3116 0.1725 -0.1198 0.3757 4.81e-03 8.90e-03 
403 Subdoligranulum -0.5921 0.2461 0.0805 0.6462 2.60e-10 1.30e-08 
436 Ruminococcus -0.3858 0.1759 0.0309 0.4251 2.21e-04 6.91e-04 
447 Clostridium -0.2774 0.1168 0.1460 0.3345 1.56e-02 2.69e-02 
448 Blautia -0.3069 -0.2049 0.0318 0.3704 5.69e-03 1.02e-02 
453 Roseburia -0.3340 0.3760 0.1454 0.5235 3.47e-04 1.00e-03 
455 Subdoligranulum -0.3862 0.3017 0.2717 0.5603 2.17e-04 6.91e-04 
507 Blautia -0.3870 -0.1137 0.2480 0.4735 2.09e-04 6.91e-04 
513 Bacteroides -0.1302 -0.1417 0.2682 0.3301 2.10e-02 3.08e-02 
622 Escherichia/Shigella -0.1947 0.1002 0.4181 0.4720 4.50e-05 2.42e-04 
1008 Lactobacillus 0.1159 -0.4167 0.1033 0.4447 4.84e-05 2.42e-04 
1403 uncl. Lachnospiraceae -0.1942 0.0149 -0.3734 0.4211 3.90e-04 1.03e-03 









The arrow of an OTU points into the direction of the presence of an OTU, whereas the 
opposite direction indicates the absence of the respective OTU. This means that many OTUs 
were present within the normal microbiota and absent within the antibiotically treated 
microbiota, as most of the arrows point into the direction of the grey circles. This is also 
indicated by negative prefixes of the principal coordinate 1 (Table 3-2). When classifying 
these OTUs it becomes obvious that many OTUs having a 97% homology to the genus 





Figure 3-8: Biplot of unweighted Bray-Curtis indices of the luminal microbiota and correlated OTUs.
Correlated OTUs contribute at least 0.5% to the overall similarity and fulfill the fdr of 0.0001. "Day 0"(n = 20)
......; "Day 4" (after antibiotic treatment; n = 20)     ; probiotic treated group at "Day 14"    , "Day 28"     and "Day
46"    ; placebo treated group at "Day 14"    , "Day 28"    and "Day 46"     ( n = 10 for all the remaining groups). 
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Figure 3-9: Biplot of weighted Bray-Curtis indices of the luminal
microbiota. "Day 0" (n = 20) ...; "Day 4" (after antibiotic treatment; n =
20)....; probiotic treated group at "Day 14"....,"Day 28".....and "Day 46"....;
placebo treated group at "Day 14"...., "Day 28".....and "Day 46".....(n = 10
for all the remaining groups). 
Weighted Bray-Curtis indices 
Whereas unweighted beta-diversity takes into account the absence and the presence of an 
OTU, weighted beta diversity "weighs" the presence of an OTU by its abundance and is 
therefore a quantitative measurement. 
Based on weighted Bray-
Curtis indices a biplot was 
generated as shown in 
Figure 3-9. The color code is 
the same as in the figures 
shown before. The principal 
coordinate 1 explains 7.3% 
of the variation between the 
samples. 3.69% variation is 
explained along the principal 
coordinate 2, followed by 
3.07% explained variation 
by the third principal 
coordinate. At a first glance 
the different colored circles 
look much more separated 
than within the biplot of the 
unweighted Bray-Curtis indices (Figure 3-7). To check for possible significant differences 
between the timepoints and the treatment groups an AMOVA was conducted. The results are 
show in Table 3-3. 
As depicted within the biplot by the grey and the red circles, a significant difference between 
the timepoints "Day 0" and "Day 4" could be confirmed, indicating a significant influence 
onto the gut microbiota due to the antibiotic treatment. Furthermore, there was a significant 
difference between the placebo and the probiotically treated group at "Day 14" and "Day 28" 
as well as "Day 46". In comparison to the initial timepoint "Day 0" there was a significant 
difference to the probiotically treated group at all three timepoints, but not to the placebo 
treated group except for timepoint "Day 14". The placebo treated microbiota seemed to be 
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similar to the initial microbiota from "Day 28" on, which could be a hint for the resilience of 
the gut microbiota. A gender-dependent difference between the treatment was not detected. 
Table 3-3: Results of the AMOVA for weighted Bray-Curtis indices of the luminal microbiota. 104 
permutations were performed. Values after Bonferroni-Holm correction for multiple testing (n = 28). Cells 
highlighted in grey show statistical significant results. 
  Time 
point 
Day 4 Day 14 Day 28 Day 46 






  Day 0   
Day 4 Antibiotic 2.8e-04 
Day 14 Placebo 
0.0179 0.0005   
VSL#3 2.8e-04 0.0122 0.0021 
Day 28 Placebo 
1 0.0480 1 0.0026   
VSL#3 0.0005 0.0146 0.0095 1 0.0146 
Day 46 Placebo 
1 0.0541 1 0.0058 1 0.0368   
VSL#3 2.8e-04 0.0541 0.0089 1 0.0057 1 0.0179   
 
A Spearman correlation was performed to have a look at OTUs that might be responsible for 
the differences of the timepoints and treatments, respectively. OTUs that showed a minimum 
contribution of 0.5% within the SIMPER analysis and fulfilled the fdr of 0.05 within the 
Spearman correlation are listed in Table 3-4. 
Table 3-4: Statistical significant results of the Spearman correlation of OTUs and weighted Bray-Curtis 
indices of the luminal microbiota. OTUs with a minimum contribution of 0.5% to the overall similarity. Fdr of 
0.05. Cells highlighted in grey: OTUs that are plotted into the biplot in Figure 3-8 fulfilling the fdr of 0.0001. 
OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
4 uncl. Lachnospiraceae 0.0422 0.2939 -0.1474 0.3315 8.99e-03 1.66e-02 
7 Blautia -0.0169 0.3322 -0.3558 0.4870 8.42e-04 2.63e-03 
8 Blautia 0.2695 0.3423 -0.1220 0.4524 1.47e-03 4.08e-03 
13 Blautia 0.0336 0.4502 -0.1352 0.4713 7.81e-06 4.88e-05 
17 uncl. Lachnospiraceae 0.3468 0.2798 0.0465 0.4481 1.22e-03 3.60e-03 
18 uncl. Lachnospiraceae 0.2674 0.1895 0.1113 0.3461 2.14e02 3.64e-02 
24 uncl. Lachnospiraceae 0.2669 0.4464 -0.0428 0.5218 9.74e-06 5.41e-05 
33 Faecalibacterium 0.1774 0.3132 -0.1488 0.3895 4.54e-03 9.86e-03 
37 Streptococcus -0.6841 0.1130 0.1652 0.7128 1.29e-14 6.45e-13 
46 Blautia 0.0633 0.4944 -0.2682 0.5660 5.14e-07 6.42e-06 
69 Sporacetigenium 0.3808 0.4855 0.2527 0.6668 9.17e-07 9.17e-06 
81 Bacteroides 0.3062 0.0539 0.2264 0.3847 5.83e-03 1.17e-02 
91 Bacteroides 0.2605 -0.0800 0.3200 0.4203 3.52e-03 8.80e-03 
173 Bacteroides 0.1318 0.1200 0.3943 0.4327 1.48e-04 5.68e-04 
182 Bacteroides 0.1281 0.0421 0.5166 0.5339 1.13e-07 1.88e-06 
247 Pseudomonas 0.3032 0.0098 -0.3228 0.4429 3.17e-03 8.34e-03 
254 Pseudomonas 0.1168 -0.1575 -0.2668 0.3311 2.19e-02 3.64e-02 
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OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
330 Turicibacter 0.3647 0.0689 0.1069 0.3863 5.73e-04 2.05e-03 
352 uncl. Peptostreptococcaceae 0.3185 0.2728 0.0938 0.4297 3.73e-03 8.87e-03 
387 uncl. Lachnospiraceae 0.2687 0.0991 0.1445 0.3208 2.06e-02 3.64e-02 
403 Subdoligranulum 0.6208 0.4374 0.0450 0.7607 1.68e-11 4.19e-10 
436 Ruminococcus 0.2038 0.3066 0.1711 0.4060 5.75e-03 1.17e-02 
447 Clostridium 0.3581 0.3329 0.1137 0.5020 7.61e-04 2.54e-03 
453 Roseburia 0.3462 0.3992 0.3160 0.6157 1.17e-04 4.86e-04 
455 Subdoligranulum 0.4154 0.2977 0.2275 0.5594 5.19e-05 2.36e-04 
507 Blautia 0.0952 0.3171 -0.0383 0.3333 3.91e-03 8.89e-03 
622 Escherichia/Shigella 0.1429 0.1463 0.4621 0.5053 3.91e-06 2.79e-05 
768 Streptococcus -0.4790 -0.0497 0.0301 0.4825 1.38e-06 1.15e-05 
1008 Lactobacillus -0.4372 0.0905 -0.0051 0.4465 1.62e-05 8.12e-05 
2490 Streptococcus -0.2987 0.1201 0.0208 0.3226 7.62e-03 1.46e-02 
 
For a better overview only OTUs that survived the fdr of 0.001 were plotted into the biplot 
within Figure 3-10. The OTUs 7, 37, 768 and 1008 point into the negative direction of the 
first principal coordinate (PCo 1 in Table 3-4) and were therefore more abundant within the 
probiotically treated group (green circles in Figure 3-10). The classification of these OTUs 
revealed three of them having a high homology to the genera Streptococcus and 
Lactobacillus. The other listed OTUs point into the direction of timepoint "Day 0" and the 
placebo treated individuals (positive PCo 1 and PCo 2), meaning that those OTUs were much 
more abundant in the placebo and at "Day 0" and tend to decrease due to antibiotic treatment. 
As within the unweighted approach OTUs with a 97% homology to Blautia and 
Lachnospiraceae seem to fall in this group (OTUs 7, 8, 13, 24 and 46). It also becomes 
obvious that OTUs that are similar to the same genus can point into opposite directed clusters. 
OTU 91 and OTU 254 point into the direction of the antibiotically treated microbiota, 
whereas the OTUs 81 and 247 point into the direction of the timepoint "Day 0" and the 
placebo treated microbiota. OTU 81 as well as OTU 91 are similar to Bacteroides, OTU 247 
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Figure 3-10: Biplot of weighted Bray-Curtis indices of the luminal microbiota and correlated OTUs.
Correlated OTUs contribute at least 0.5% to the overall similarity and fulfilled the fdr of 0.0001. "Day 0" (n =
20).....; "Day 4" (after antibiotic treatment; n = 20).....; probiotic treated group at "Day 14"....., "Day 28".....and




In addition to the correlation analysis the metastats command was used to determine if any 
OTUs are differentially represented between the different timepoints/treatment groups. Again 
only those OTUs were analyzed that contributed at least 0.5% to the overall contribution 
(SIMPER analysis). Table 3-5 shows the results of the metastats analysis between the placebo 
and the probiotically treated group at the three different timepoints. OTUs which were absent 
in one timepoint, but present at the other timepoint are listed as "appears" or "disappears". At 
timepoint "Day 14" there could be found more OTUs that differ in their abundance between 
the placebo and the probiotic treatment than at the timepoints "Day 28" and "Day 46". 
Interestingly, OTUs having homology to Blautia (OTUs 7, 8, 13) and Subdoligranulum 
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(OTUs 403 and 455) seemed to be significantly decreased within the probiotic group at "Day 
14". These differences could not be found within the other timepoints. A difference between 
the placebo and the probiotic group within all three timepoints was OTU 37, which was found 
to have a 97% homology to Streptococcus and highly abundant within the probiotic groups. 
On the other hand there was not a single OTU significantly decreased within all timepoints 
due to the probiotic therapy. 
Table 3-5: Statistical significant results of the metastats analysis comparing the placebo and probiotic 
group at the respective timepoints. Ratio is relative to the placebo. 1000 permutations were performed. p 
values after Bonferroni-Holm correction for multiple testing. Appears= present in probiotic, but absent in 
placebo group, Disappears= absent in probiotic group, but present in placebo. n = 10 for each groups. Cells 
highlighted in grey: Indicator species at 97% level. 
Day 14 Day 28 Day 46 
OTU number/BLAST hit ratio (log10) ratio (log10)) ratio (log10) 
4 uncl. Lachnospiraceae 0.108 (-0.966) 
7 Blautia 0.325 (-0.488) 
8 Blautia disappears 
13 Blautia 0.252 (-0.598) 
37 Streptococcus 5.762 (0.761) 5.132 (0.710) 3.62 (0.559) 
69 Sporacetigenium 0.076 (-1.121) 0.081 (-1.089) 
80 Dialister 0.353 (-0.453) 
254 Pseudomonas disappears 
352 uncl. Peptostrepococcaceae 0.227 (-0.644) 
403 Subdoligranulum 0.123 (-0.910) 0.171 (-0.768) 
447 Clostridium 0.054 (-1.266) disappears 
453 Roseburia disappears 
455 Subdoligranulum disappears 
768 Streptococcus appears appears 
1008 Lactobacillus appears 
1378 uncl. Lachnospiraceae appears 
2490 Streptococcus disappears 
4732 Prevotella disappears 
6245 Lactobacillus disappears 
6611 Streptococcus appears 
 
Since the AMOVA showed a significant difference between the initial and the antibiotically 
treated microbiota, it was expected for some OTUs to be over- or underrepresented within one 
of the groups within the metastats analysis. Further the difference of the placebo and the 
probiotic group at the end of the study ("Day 46") was compared to the initial composition of 
"Day 0". 
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Table 3-6: Statistical significant results of the metastats analysis comparing timepoint "Day 0" and 
different groups. Ratio is relative to "Day 0". 1000 permutations were performed. p values after Bonferroni-
Holm correction for multiple testing. Disappears= absent at "Day 4"/"Day 46", but present at "Day 0". n = 20 for 
"Day 0" and "Day 4"; n = 10 for each of the other groups. Cells highlighted in grey: Indicator species at 97% 
level. 
Day 4 Day 46 Placebo Day 46 Probiotic 
OTU number/BLAST hit ratio (log10) ratio (log10) ratio (log10) 
13 Blautia 0.275 (-0.561) 
17 uncl. Lachnospiraceae 0.371 (-0.431) 0.219 (-0.660) 
18 uncl. Lachnospiraceae 0.593 (-0.227) 0.165 (-0.782) 
24 uncl. Lachnospiraceae 0.189 (-0.724) 0.485 (-0.313) 
33 Faecalibacterium 0.022 (-1.664) 
37 Streptococcus 5.01 (0.699) 
46 Blautia 0.099 (-1.006) 
69 Sporacetigenium 0.147 (-0.8209) 
81 Bacteroides 13.18 (1.120) 
91 Bacteroides 5.56 (0.745) 
182 Bacteroides 0.258 (-0.585) 
447 Clostridium 0.014 (-1.851) disappears 
1839 Bacteroides disappears 
 
Table 3-6 shows the results of the metastats analysis. Due to the antibiotic treatment (column 
"Day 4") all OTUs listed in the table, except for the OTUs 81 and 91, showed a significant 
decrease. The classification of these OTUs revealed a 97% homology to the family 
Lachnospiraceae and the genera Blautia, Faecalibacterium and Clostridium. OTU 81 and 
OTU 91, which showed a higher abundance due to the antibiotic, were all classified as 
Bacteroides. 
Regeneration of the microbiota shown by the comparison of "Day 46" compared to "Day 0" 
revealed that there was still a decrease within the OTU 18 (having homology to 
Lachnospiraceae) in the placebo treated group. The probiotic group indicated differences in 
two other OTUs also having homology to Lachnospiraceae. Further a significant decrease in 
three OTUs with homology to Sporacetigenium, Bacteroides, and Clostridium was identified. 
Many of the OTUs that were significantly decreased by the antibiotic treatment could recover 
during time, not very much influenced by the probiotic. 
The comparison between the placebo or probiotic group of the timepoints "Day 14" or "Day 
28" to timepoint "Day 0" can draw a clearer picture when certain OTUs recover (Table 3-7). 
All OTUs that were characterized as Blautia and were significantly decreased due to the 
antibiotic treatment seem to recover very fast as there was no significant difference within the 
comparison of "Day 0" and "Day 14", independent of the probiotic therapy. OTU 33 
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(Faecalibacterium) needed a longer time period for recovery as this OTU was still 
significantly decreased at "Day 14" and "Day 28", but not at "Day 46" (Table 3-6), again 
independent of the probiotic therapy. Very high abundant within the probiotic group 
compared to "Day 0" was OTU 37 (Streptococcus) at "Day 14" and at "Day 28" as well as the 
OTU 768 (Streptococcus) at "Day 14". 
Table 3-7: Statistical significant results of the metastats analysis comparing timepoint "Day 0" and 
different groups. Ratio is relative to "Day 0". 1000 permutations were performed. p values after Bonferroni-
Holm correction for multiple testing. Disappears= absent at "Day 14"/"Day 28", but present at "Day 0". Appears 
= present at "Day 14"/"Day 28", but absent at "Day 0". n = 20 for "Day 0"; n = 10 for each of the other groups. 
Cells highlighted in grey: Indicator species at 97% level. 
Day 14 Placebo Day 14 Probiotic Day 28 Placebo Day 28 Probiotic
OTU number/ 
BLAST hit ratio (log10) ratio (log10) ratio (log10) ratio (log10 
17 uncl. Lachnosp. 0.095 (-1.020) 0.342 (-0.466)  
18 uncl. Lachnosp. disappears 0.646 (-0.190) 0.170 (-0.769) 
24 uncl. Lachnosp. 0.203 (-0.692) 0.273 (-0.564) 
33 Faecalibacterium 0.075 (-1.1268) 0.117 (-0.932) 0.565 (-0.248) 0.141 (-0.850) 
37 Streptococcus 5.795 (0.763) 5.58 (0.747) 
69 Sporacetigenium 0.103 (-0.988)  
447  Clostridium 0.06 (-1.189) 
768 Streptococcus 42.95 (1.633)  
2490 Streptococcus disappears  
4286 Lactobacillus appears  
6245 Lactobacillus appears  
6611 Streptococcus appears  
 
Apart from the metastats command the indicator species command implemented in 
MOTHUR can be used. This will output OTUs that define and characterize a timepoint or 
treatment. As for the metastats approach only OTUs with a minimum contribution of 0.5 % 
and 1% were included within the analysis (as revealed by SIMPER analysis), respectively. 
The indicator species command was performed on species (97% identity) and on genus level 
(95% identity). 
On species level with a contribution of at least 0.5% the OTUs 24 and 33 were identified as 
indicator species between the groups "Day 0" and "Day 4", which is after the antibiotic 
treatment. As shown in Table 3-6 these OTUs have a homology to the family 
Lachnospiraceae and the genus Faecalibacterium and are decreased due to the antibiotic 
treatment. Comparing the placebo and the probiotic group at the respective timepoints there 
were no indicator species found for the timepoints "Day 14" and "Day 46". For the timepoint 
"Day 28" the OTU 37 (Streptococcus) tended (pcorr = 0.0837) to be an indicator species when 
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1% contribution was set as minimum. Comparing the probiotic group of "Day 28" to the 
initial timepoint "Day 0" OTU 37 (Streptococcus) again was designed as indicator species 
highly abundant within the probiotically treated group (with 1% contribution). Comparing the 
other timepoints to the initial timepoint "Day 0" no indicator species could be found. 
On genus level (95% identity) the OTUs 20 (Faecalibacterium), 9 and 12 (both 
Lachnospiraceae), which had a contribution of at least 0.5% were identified as indicator 
species between the timepoints "Day 0" and "Day 4" and therefore characterized the 
antibiotically treated microbiota compared to the normal one. Further the OTUs 2 and 7 
(contribution of at least 1%) tended to be an indicator species (OTU 2 pcorr = 0.0561 and 
OTU 7 pcorr = 0.08622). Both OTUs have at least 95% similarity to the genus Blautia. 
Comparing the placebo to the probiotic group there were no indicator species found at each of 
the respective timepoints. Comparing the two treatment groups at the respective timepoints to 
the initial timepoint "Day 0", the OTU 12 (Lachnospiraceae) characterized the difference 
between the placebo group at "Day 14" and the "Day 0" as an indicator species. Also for the 
probiotic group at this timepoint "Day 14" OTU 12 was found. In addition OTU 9 
(Lachnospiraceae) tended to be characteristic (pcorr = 0.0792) when taking into account only 
OTUs with a contribution of 1%. Since these two OTUs were decreased due to the antibiotic 
and still showed a lower abundance within the placebo and probiotic group than within the 
initial composition, this result shows that the two OTU were not able to recover until "Day 
14". The OTU 24 (Streptococcus) tended to be an indicator species between the probiotic 
group of "Day 28" and "Day 0" at 1% contribution level (pcorr = 0.08712). 
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Since the analysis shown before was OTU-based, the correlation showed OTUs that are 
responsible for the clustering of the treatment groups and timepoints. Another correlation was 
performed taking into account the whole taxa on genus level. Only taxa contributing at least 
0.5% to the overall similarity were included. 
Table 3-8: Statistical significant results of the Spearman correlation of the taxa on genus level and 
weighted Bray-Curtis coefficients of the luminal microbiota. Taxa with a minimum contribution of 0.5% to 
the overall similarity. Fdr of 0.05. Cells highlighted in grey: Taxa that are plotted into the biplot in Figure 3-11 
fulfilling the fdr of 0.001. 
Taxon PCo 1 PCo 2 PCo 3 length p.min q.val 
Alistipes 0.1023 -0.2255 0.2970 0.3866 8.09e-03 1.70e-02 
Bacteroides 0.2386 -0.2206 0.4316 0.5402 2.20e-05 1.32e-04 
uncl. Bacteroidales -0.0125 -0.4845 -0.0064 0.4847 9.81e-07 8.24e-06 
Blautia -0.0941 0.5951 -0.3446 0.6941 1.98e-10 2.78e-09 
Clostridium 0.4123 0.3024 0.1911 0.5458 6.08e-05 2.93e-04 
Coprococcus 0.3998 0.1594 0.1361 0.4514 1.13e-04 3.96e-04 
Dorea 0.1155 0.2755 -0.1573 0.3376 1.66e-02 3.32e-02 
Escherichia/Shigella 0.1225 0.0825 0.4076 0.4335 7.69e-05 3.06e-04 
Holdemania 0.0199 -0.3166 0.08371 0.3281 3.99e-03 9.31e-03 
uncl. Lachnospiraceae 0.2516 0.3089 -0.0681 0.4042 5.29e-03 1.17e-02 
Lactobacillus -0.4068 0.0702 -0.1018 0.4252 8.01e-05 3.06e-04 
uncl. Lactobacillales -0.6440 -0.1618 -0.0492 0.6659 1.47e-12 3.08e-11 
uncl. Peptostreptococcaceae 0.3331 0.2185 0.1318 0.4196 2.12e-03 5.94e-03 
Pseudomonas 0.3150 0.0043 -0.3312 0.4571 2.29e-03 6.02e-03 
uncl. Pseudomonadaceae 0.2025 -0.1490 -0.2615 0.3628 2.58e-02 4.92e-02 
Roseburia 0.4382 0.3878 0.1422 0.6022 1.54e-05 1.08e-04 
Ruminococcus 0.1765 0.3268 0.0930 0.3829 2.71e-03 6.70e-03 
uncl. Ruminococcaceae 0.3636 -0.0972 0.0872 0.3863 6.02e-04 1.95e-03 
Sporacetigenium 0.3773 0.4116 0.2016 0.5936 6.28e-05 2.93e-04 
Streptococcus -0.7057 0.1402 0.1004 0.7265 7.29e-16 3.06e-14 
Subdoligranulum 0.5039 0.3189 0.0408 0.5977 2.73e-07 2.86e-06 
Turicibacter 0.3496 0.0365 0.0901 0.3628 1.09e-03 3.27e-03 
 
Table 3-8 shows the results of the correlation of the taxa on genus level. Eleven of the taxa are 
plotted into the biplot in Figure 3-11. 
Table 3-8 and Figure 3-11 show that the genus Bacteroides and the associated order 
Bacteroidales, both having a negative principal coordinate 2, were highly abundant within the 
antibiotically treated microbiota. The genera having a positive principal coordinate 1 and 2 
were therefore highly abundant within the normal microbiota and tended to decrease due to 
antibiotic treatment. Families like Lachnospiraceae and Peptostreptococcaceae, but also 
genera like Clostridium, Coprococcus, Escherichia, Roseburia, Ruminococcus, 
Sporacetigenium and Turicibacter seem to belong to this group. The probiotically treated 
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microbiota is characterized by Lactobacillales and by Lactobacillus as well as Streptococcus 
with a high negative value for the principal coordinate 1. The genus Blautia represents a state 
between the initial and the probiotically treated microbiota and was highly diminished in the 







Figure 3-11: Biplot of weighted Bray-Curtis distances of the luminal microbiota and correlated taxa.
Correlated taxa contribute at least 0.5% to the overall similarity and fulfill a fdr of 0.001. "Day 0" (n = 20).....;
"Day 4" (after antibiotic treatment; n = 20).....; probiotic treated group at "Day 14"....., "Day 28".....and "Day
46".....; placebo treated group at "Day 14"....., "Day 28".....and "Day 46".....(n = 10 for all the remaining groups). 
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3.2 16S rRNA and 16S rRNA gene amplicon libraries from mucosa-
associated samples 
In addition to the fecal samples, sigmoid biopsy samples had been collected via 
sigmoidoscopy on three different timepoints. The first at timepoint "Day 0", the second after 
the antibiotic treatment at "Day 4" and the third at timepoint "Day 46" from both the placebo 
as well as the probiotically treated group. From these biopsy samples DNA and RNA were 
extracted and RNA was reverse transcribed into cDNA. Amplicon libraries from DNA as well 
as from cDNA were generated by amplifying the V1-V2 region within a barcode-tagged PCR 
approach and sequenced via 454 pyrosequencing. 
This resulted in 920.064 reads. The reads were split according to their barcode and checked 
for their mean Phred quality score with the software PANGEA (Giongo et al. 2010). Further 
MOTHUR was used (Schloss et al. 2009) to eliminate reads with no perfect match to the 
primer, ambiguous bases, homopolymers and a length less than 200 bp. Also chimerical 
sequences were eliminated. The denoising step resulted in 808.430 cleaned sequences. The 
uneven distribution of sequences per sample (1.506 until 34.742 sequences per sample, 
median 4.184) was ameliorated by normalizing the number of sequences of each sample to 
1.506. This resulted in the final data set of 180.720 sequences. 
A classification against the reference sequences of RDP was performed for a first overview. 
In addition an OTU-based analysis was performed. 
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Figure 3-12: Phylum distribution of the (A) present mucosa-associated microbiota and (B) active
mucosa-associated microbiota at timepoint "Day 0". Description in percent. n = 20. 
(A) 
(B) 
3.2.1 First classification of the denoised data set of the mucosa-associated 
microbiota 
To obtain a first impression of the phylum distribution within the mucosa-associated 
microbiota, the sequences of all twenty individuals at timepoint "Day 0" were classified using 
the classifier of the Ribosomal Database Project (RDP). As shown in Figure 3-12 (A) the four 
main abundant phyla within the present mucosa-associated microbiota are Firmicutes, 
Bacteroidetes, Proteobacteria and Actinobacteria. This is an expected picture of the phyla 
distribution of healthy individuals. The small amount specified as "Others" represents phyla 
like Acidobacteria, Cyanobacteria, Deinococcus-Thermus, Fusobacteria, Verrucomicrobia 
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However, the phylum distribution of individual 10 (D10) is characterized by a huge amount of 
Spirochaetes, which is very abnormal for healthy individuals. Since this phylum was not 
found in the other individuals and the effect onto the bacterial community is unclear, 
individual 10 was discarded from further analysis. 
The phylum distribution of the active mucosa-associated microbiota, as depicted in Figure 
3-12 (B), looks quite similar. Again the four main phyla are Firmicutes, Bacteroidetes, 
Proteobacteria and Actinobacteria. And again "Others" represents phyla like Acidobacteria, 
Cyanobacteria, Deinococcus-Thermus, Fusobacteria and some unclassified bacteria. In 
contrast to the present microbiota the phylum Verrucomicrobia was not found in the active 
one. Individual 10 also shows a very high amount of active Spirochaetes. As decided 
previously individual 10 was discarded from further analysis. 
Based on the 180.720 cleaned sequences 171.684 were used for further analysis due to the 
elimination of individual 10. 
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The classification of the remaining timepoints gave a simple overview onto the effect of the 
antibiotic and the subsequent probiotic or placebo therapy. The two main phyla, Firmicutes 
















Based on the classification the median and the quartiles were calculated for each treatment 
and plotted into boxplots (Figure 3-13). Due to the antibiotic treatment a significant decrease 
within present Firmicutes (pcorr = 0.0247) could be observed. In active Firmicutes (pcorr = 
0.3736) as well as within present and active Bacteroidetes (present: pcorr = 0.0987; active: pcorr 
Figure 3-13: Changes in the two main mucosa-associated phyla due to antibiotic treatment and
subsequent placebo or probiotic therapy. (A) Present Firmicutes. (B) Active Firmicutes. (C) Present
Bacteroidetes. (D) Active Bacteroidetes. Median, upper and lower quartile as well as upper and lower wisker
are plotted. Grey (D0): Timepoint "Day 0" (n = 19), Red (D4): Timepoint "Day 4" after antibiotic treatment (n =
19), blue (D46): Timepoint "Day 46" after placebo therapy (n = 10), green (D46VSL): Timepoint "Day 46" after
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= 0.2268) antibiotic therapy resulted in an increase of the respective phyla, but this increase 
was not significant. The subsequent allocation to placebo or the probiotic therapy (the 
randomization was appropriate) revealed no difference at timepoint "Day 46" in neither active 
or present Bacteroidetes (active: pcorr = 0.633 and present: pcorr = 0.3999) nor in active or 
present Firmicutes (active: pcorr = 0.9934, present: pcorr = 1), respectively. The comparison 
between the timepoints "Day 0" and "Day 46" did not show any significant difference in any 
of the groups, indicating a good recovery of active and present Firmicutes as well as 
Bacteroidetes. With regard to the phylum Proteobacteria, which was highly abundant in some 
of the study participants in its active and in the present form (figure 3-12 and 3-13), the 
median for present Proteobacteria was around 10% and did not respond to any of the 
treatments. The same applies for active Proteobacteria, which had a mean abundance of about 
12%. 
For deeper analysis an OTU-based analysis was performed for the active and the present 
mucosa-associated microbiota. 
3.2.2 OTU-based analysis 
The 171.684 sequences were aligned according to the Needleman-Wunsh algorithm. A 
distance matrix was then generated by calculating the uncorrected pair wise distances between 
the aligned sequences. Based on the distances the sequences were assigned into OTUs at the 
levels of 97% (species level) and 95% (genus level) according to the average neighbor 
method. The final dataset of 171.684 sequences was grouped into 5.986 OTUs on species 
level, which are the basis for the subsequent analysis. 
3.2.2.1 Alpha-Diversity 
As far as the Good´s coverage of the remaining samples is concerned, it was in the range of 
91.43% to 98.67% (median = 95.62%) for the present and between 86.39% and 98.07% 
(median = 93.23%) for the active microbiota. In addition to the Good´s coverage rarefaction 
curves of the sample with the best and the worst coverage were plotted for the DNA and the 
cDNA samples, respectively (Figure 3-14). 
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Figure 3-14: Rarefaction curves of the active and the present mucosa-associated microbiota with maximal, 
minimal and medial coverage. 
The rarefaction curves and especially the Good´s coverages show that most of the bacteria 
present in the samples could be found. This indicates an adequate sampling. Therefore the 
analysis was continued with the different measurements of alpha diversity, which analyses the 
composition within a certain sample. 
For this purpose the measurement of the observed OTUs, the Chao 1 richness estimator as 
well as the Shannon index were calculated. The individual values can be found within the 
appendix in Table 7-3, whereas the median and the quartiles of each parameter are plotted 
into the following boxplots. 
For all three of the calculated parameters (observed OTUs, Chao1 richness estimator and 
Shannon index) there were no gender-specific effects in either of the comparisons. 
Furthermore the differences between the timepoints "Day 0" and "Day 4" were calculated and 
tested with the Wilcoxon rank sum test comparing the later placebo to the later probiotic 
group. The results were not significant indicating an appropriate randomization. All unpaired 
tests were performed with the exact Wilcoxon rank sum test, whereas the exact Wilcoxon 
signed rank test was used for paired samples. 
 










Figure 3-15: Boxplots of the observed OTUs for the present (A) and the active (B) mucosa-associated 
microbiota. Median, upper and lower quartile as well as upper and lower whisker are plotted. Grey (D0): 
Timepoint "Day 0" (n = 19), Red (D4): Timepoint "Day 4" after antibiotic treatment (n = 19), blue (D46): 
Timepoint "Day 46" after placebo therapy (n = 10), green (D46VSL): Timepoint "Day 46" after probiotic 
therapy (n = 9). * statistically significant compared to timepoint "Day 0" at a level of 0.05 after Bonferroni-Holm 
correction (n = 3). 
For the observed OTUs one could see a significant decrease due to the antibiotic treatment 
from timepoint "Day 0" to "Day 4" in the present (Figure 3-15: (A); pcorr = 2.8e-04) as well in 
the active mucosa-associated bacteria (Figure 3-15: (B); pcorr = 0.0048). However, in both 
cases there was no difference between the placebo and the probiotic treatment (pcorr = 0.9744 
for present and active microbiota), which means that both therapies resulted in nearly the 
same amount of observed OTUs at the end of the study. Further there was no significant 
difference between the timepoints "Day 0" and "Day 46" (pcorr = 0.2927 (present); pcorr > 1 
(active)) within the present and the active microbiota, respectively. 
The same picture can be seen if the richness is estimated by the Chao1 richness estimator. The 
antibiotic treatment led to a significant decrease within the present (Figure 3-16: (A); pcorr = 
0.0053) microbiota as well as for the active bacteria (Figure 3-16: (B); pcorr = 0.0029), but 
again there was no difference between the probiotic and the placebo therapy in the present 
(pcorr = 0.6607) as well as in the active microbiota (pcorr = 0.9744) and there was no difference 






























Figure 3-16: Boxplots of the Chao1 species richness for the present (A) and the active (B) and Shannon H´ 
for the present (C) and the active (D) mucosa-associated microbiota. Median, upper and lower quartile as 
well as upper and lower whisker are plotted. Grey (D0): Timepoint "Day 0" (n = 19), Red (D4): Timepoint "Day 
4" after antibiotic treatment (n = 19), blue (D46): Timepoint "Day 46" after placebo therapy (n = 10), green 
(D46VSL): Timepoint "Day 46" after probiotic therapy (n = 9). * statistically significant compared to timepoint 
"Day 0" at a level of 0.05 after Bonferroni-Holm correction (n = 3). 
When combining richness and evenness, diversity can be measured. In this case there was a 
significant decrease in the present microbiota (Figure 3-16: (C); pcorr = 2.8e-04 due to the 
antibiotic treatment, but not within the active microbiota (Figure 3-16: (D); pcorr = 0.0874). 
The effect of the probiotic compared to the placebo was not significant in both cases (pcorr = 
0.3384 for the present bacteria; pcorr = 0.9744 for the active bacteria). The difference between 
the timepoints "Day 0" and "Day 46" was not significant within the present (pcorr = 0.2927) as 
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Figure 3-17: Biplot of the unweighted Bray-Curtis indices of the
present and active mucosa-associated microbiota. "Day 0" (n = 19),
present (.....) and active (.....); "Day 4" (after antibiotic treatment; n = 19),
present (.....) and active (.....); "Day 46" (placebo group; n = 10), present
(.....) and active (.....); "Day 46” (probiotic group; n = 9), present (.....)
and active (.....). 
In summary, the antibiotic treatment resulted in a more or less significant decrease in richness 
and diversity within the active and the present mucosa-associated microbiota. The 
regeneration of the microbiota was probiotic-independent. Further, richness as well as 
diversity seemed to recover to a high amount, nearly similar to the initial state, as there were 
no differences between the timepoints "Day 0" and "Day 46". 
3.2.2.2 Beta-diversity 
To investigate diversity between the samples, the unweighted and the weighted Bray-Curtis 
indices were calculated with the R package vegan. The indices were then converted into data 
points by a PCoA and plotted into a biplot. 
Unweighted Bray-Curtis indices 
Unweighted beta-diversity 
takes into account the 
absence and the presence of 
an OTU. Figure 3-17 shows 
the biplot of the 
unweighted Bray-Curtis 
indices of the present and 
the active mucosa-
associated microbiota. The 
principal coordinate 1 
represents 7% of the 
variation between the 
clusters, followed by 5.3% 
represented by the principal 
..coordinate 2. The third axis 
..explains 4.74%. It seems 
..that if the red and pink 
..circles, which indicate the 
timepoint "Day 4" after the antibiotic treatment, are separated compared to the remaining 
circles. To test for separated clusters formed by the treatments, an AMOVA was performed. 
The AMOVA showed that the clusters of the present compared to the active bacteria were not 
significant in either of the timepoints (pcorr > 1). There were no gender-dependant effects 
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within the active as well as in the present microbiota. Further there was no significant 
difference between the later probiotic and the later placebo group at either timepoint "Day 0" 
or "Day 4", indicating an appropriate randomization. Two more AMOVAs were performed to 
test between the treatments within the active and the present microbiota, respectively. The 
AMOVA of the present bacteria (Table 3-9 (A)) showed significant differences between the 
antibiotically treated (timepoints "Day 4", red circles) and the initial microbial composition at 
"Day 0" (black circles) as well as to both treatment groups (placebo and probiotic) at 
timepoint "Day 46" (dark green and dark blue circles). Further the probiotic group seemed 
still significantly altered at the end of the study (dark green circles) compared to the initial 
composition (black circles). However, there was no significant difference between the placebo 
and the probiotic treatment at timepoint "Day 46". 
Table 3-9: Results of the AMOVA for unweighted Bray-Curtis indices of the (A) present and the (B) active 
mucosa-associated microbiota. 104 permutations were performed. Cells highlighted in grey show statistical 
significant results after Bonferroni-Holm correction for multiple testing (n = 6). 
Timepoint 
Day 4 Day 46 
Treatment Day 0 Antibiotic Placebo VSL#3 
Day 0 6e-05 0.3255 0.0399 






Day 4 Day 46 
Treatment Day 0 Antibiotic Placebo VSL#3 
Day 0 6e-05 0.0616 0.0616 





The results of the AMOVA for the active mucosa-associated microbiota revealed the results 
presented in Table 3-9 (B). There was a significant difference of the clusters formed by 
timepoint "Day 4" (pink circles) and "Day 0" (grey circles) as well as between "Day 4" and 
the placebo as well as the probiotic group of "Day 46" (light blue and light green circles). 
Again there was no difference between the placebo and the probiotic group. 
To get an idea which OTUs were present in a specific cluster and therefore absent in another 
one, a Spearman correlation was conducted, correlating the OTUs to the axes of the biplot. 
Based on a minimum contribution of the OTUs of 0.5% to the overall similarity within a 
(A) 
(B) 
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SIMPER analysis, OTUs that fulfilled the a false-discovery rate of 0.05 are shown in Table 
3-10. 
Table 3-10: Statistical significant results of the Spearman correlation of OTUs to unweighted Bray-Curtis 
indices of the present and the active mucosa-associated microbiota. OTUs with a minimum contribution of 
0.5% to the overall similarity. Fdr of 0.05. Cells highlighted in grey: OTUs that are plotted into the biplot in 
Figure 3-18 fulfilling the fdr of 1e-07. 
OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
26 Faecalibacterium 0.5340 0.0988 0.2470 0.5966 2.83e-09 2.21e-08 
27 uncl. Lachnospiraceae 0.2327 -0.0323 -0.0965 0.2540 3.81e-02 4.95e-02 
30 Bacteroides 0.0699 0.5704 -0.0932 0.5822 1.04e-10 1.62e-09 
32 Parabacteroides 0.3121 -0.1654 0.0876 0.3639 2.17e-03 3.68e-03 
34 Faecalibacterium 0.4869 0.3530 0.1369 0.6167 1.19e-07 5.15e-07 
38 Faecalibacterium 0.5028 0.0101 0.1664 0.5297 3.57e-08 1.99e-07 
40 Subdoligranulum 0.6037 0.2333 -0.1210 0.6584 3.49e-12 8.63e-11 
46 Coprobacillus 0.3891 0.3198 -0.0113 0.5038 5.64e-05 1.33e-04 
47 Blautia 0.6281 0.0255 0.2513 0.6770 2.22e-13 8.65e-12 
48 uncl. Peptostreptococcaceae 0.3609 0.1524 0.2142 0.4465 2.39e-04 4.79e-04 
51 uncl. Peptostreptococcaceae 0.4449 0.1193 0.0065 0.4607 2.12e-06 6.88e-06 
56 Sutterella 0.3985 0.2170 0.1180 0.4688 3.39e-05 8.26e-05 
65 Blautia 0.6595 0.0050 0.2155 0.6938 4.43e-15 3.45e-13 
76 uncl. Lachnospiraceae 0.5363 0.0669 0.1936 0.5741 2.33e-09 2.02e-08 
81 uncl. Lachnospiraceae 0.4547 0.1817 -0.2835 0.5658 1.12e-06 3.96e-06 
91 uncl. Lachnospiraceae 0.5448 0.02300 -0.0290 0.5461 1.11e-09 1.23e-08 
101 Ralstonia -0.2653 0.4513 -0.0804 0.5296 1.40e-06 4.76e-06 
119 Bacteroides 0.35155 0.1184 -0.0833 0.3802 3.76e-04 7.16e-04 
154 uncl. Lachnospiraceae 0.38711 0.0171 -0.2282 0.4497 6.28e-05 1.44e-04 
166 Holdemania -0.0457 0.0415 -0.2453 0.2530 2.56e-02 3.50e-02 
196 Roseburia 0.0436 0.0726 0.3832 0.3924 7.74e-02 1.68e-04 
197 Sphingobium -0.1968 0.4688 0.0320 0.5095 4.31e-07 1.77e-06 
198 uncl. Lachnospiraceae -0.1351 -0.1245 0.6015 0.6289 4.42e-12 8.63e-11 
220 Collinsella 0.24541 0.2166 -0.4914 0.5904 8.50e-08 4.15e-07 
231 Eubacterium -0.4192 -0.1371 0.1216 0.4575 1.03e-05 2.88e-05 
246 Streptococcus -0.1279 0.1992 0.2411 0.3379 2.93e-02 3.94e-02 
267 Finegoldia 0.0899 0.5263 0.3929 0.6629 5.45e-09 3.87e-08 
268 Escherichia/Shigella -0.0332 0.4568 0.3210 0.5593 9.73e-07 3.61e-06 
279 Roseburia 0.0364 0.0034 0.5010 0.5023 4.12e-08 2.14e-07 
291 Oscillibacter 0.3113 -0.0798 0.3230 0.4556 1.37e-03 2.43e-03 
293 Coprobacillus 0.1480 0.2700 0.0879 0.3202 1.10e-02 1.68e-02 
294 Streptococcus 0.0292 0.4347 0.4611 0.6343 7.31e-07 2.85e-06 
320 uncl. Erysipelotrichaceae -0.1169 -0.3089 0.1375 0.3578 2.48e-03 4.11e-03 
349 Eubacterium 0.1106 0.2519 -0.2431 0.3671 2.06e-02 2.97e-02 
362 uncl. Lachnospiraceae 0.5200 0.0059 0.1818 0.5509 9.12e-09 5.93e-08 
363 Bacteroide 0.1590 0.0498 -0.2361 0.2890 3.43e-02 4.54e-02 
364 Subdoligranulum 0.4314 0.3157 -0.2437 0.5874 4.97e-06 1.49e-05 
365 Roseburia 0.5409 0.1268 0.0731 0.5604 1.56e-09 1.52e-08 
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OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
384 Faecalibacterium 0.4123 0.1200 0.1253 0.4473 1.55e-05 4.16e-05 
386 Faecalibacterium 0.5086 0.1717 -0.0701 0.5413 2.28e-08 1.37e-07 
392 Coprococcus 0.1351 0.0570 -0.4043 0.4301 2.45e-05 6.16e-05 
394 Bacteroides -0.0051 -0.0669 -0.3252 0.3320 1.25e-03 2.26e-03 
624 Holdemania -0.2415 -0.0669 -0.4056 0.4768 2.27e-05 5.90e-05 
631 Prevotella 0.1432 0.3468 0.0245 0.3760 4.71e-04 8.75e-04 
661 Enterococcus -0.2793 -0.0437 -0.0652 0.2902 7.84e-03 1.22e-02 
668 Brevundimonas 0.1772 0.3691 0.1042 0.4225 1.60e-04 3.27e-04 
699 uncl. Erysipelotrichaceae -0.0248 -0.2548 0.1788 0.3122 1.87e-02 2.75e-02 
763 Methylobacterium 0.08159 0.4358 -0.0312 0.4445 3.77e-06 1.18e-05 
771 uncl. Incertae Sedis_XI 0.2092 0.4875 0.1448 0.5499 1.13e-07 5.15e-07 
776 Roseburia 0.0111 -0.2883 0.4289 0.5170 5.77e-06 1.67e-05 
821 Blautia -0.0918 -0.1707 0.3065 0.3626 2.73e-03 4.44e-03 
1071 Stenotrophomonas -0.0627 0.2593 -0.0083 0.2669 1.60e-02 2.40e-02 
1252 Coprobacillus -0.0081 -0.1323 0.5549 0.5705 4.49e-10 5.83e-09 
1291 Holdemania -0.2565 0.0944 -0.3564 0.4491 2.99e-04 5.83e-04 
1398 Pseudomonas -0.0726 0.3786 -0.0320 0.3868 9.83e-05 2.07e-04 
1426 Faecalibacterium -0.0749 -0.1949 0.2870 0.3549 5.88e-03 9.36e-03 
1453 Lactobacillus 0.0699 0.0184 0.3196 0.3276 1.59e-03 2.75e-03 
1498 uncl. Prevotellaceae 0.0943 0.2505 -0.0248 0.2688 2.15e-02 3.00e-02 
1517 Sutterella 0.3863 0.1008 -0.0207 0.3998 6.54e-05 1.46e-04 
1786 Blautia -0.0812 -0.0740 0.2507 0.2737 2.14e-02 3.00e-02 
 
To depict in a biplot in which direction the OTUs point, the fdr was increased to 1e-07 
resulting in 12 OTUs (highlighted in grey in Table 3-10). Figure 3-18 shows the resulting 
biplot with the correlated OTUs. OTUs with a positive PCo 1 point into the direction of the 
initial composition at timepoint "Day 0" and therefore into the opposite direction of the 
antibiotic treatment of "Day 4". Many of those OTUs have a homology to the genera Blautia, 
Faecalibacterium and the family Lachnospiraceae. Those genera were therefore present 
within the normal microbiota at the initial timepoint "Day 0", but absent within the 
antibiotically treated microbiota. OTUs with a negative first principal coordinate and a 
positive second principal coordinate might show into the direction of the probiotic group of 
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Figure 3-18: Biplot of unweighted Bray-Curtis indices of the present and active mucosa-associated
microbiota and OTUs correlated to the axes. Correlated OTUs contribute at least 0.5% to the overall
similarity and fulfilled the fdr of 1e-07. "Day 0" (n = 19), present (.....) and active (.....); "Day 4" (after
antibiotic treatment, n = 19), present (.....) and active (.....); "Day 46" placebo group (n = 10), present (.....) and
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Figure 3-19: Biplot of weighted Bray-Curtis indices of the present and 
active mucosa-associated microbiota. "Day 0" (n = 19), present (.....) and 
active (.....); "Day 4" (after antibiotic treatment; n = 19), present (.....) and 
active (.....); "Day 46" placebo group (n = 10), present (.....) and active (.....); 
"Day 46" probiotic group (n = 9), present (.....) and active (.....). 
Weighted Bray-Curtis indices 
As for the unweighted Bray-Curtis, a biplot was designed for the weighted Bray-Curtis 
indices, taking into account the abundances of the different OTUs. Figure 3-19 shows the 
result of the PCoA of 
weighted Bray-Curtis 
indices of the present and 
active mucosa-associated 
microbiota at the several 
treatments/timepoints. 
The highest variation of 
7.74% is explained by the 
principal coordinate 1. 
The second PCo 
represents nearly 7% of 
the variation and the third 
PCo 5.22%. In general 
the lighter circles, 
representing the active 
bacteria, do not seem to 
separate very much from 
the darker circles, 
representing the present 
bacteria, in either of the treatment groups. The antibiotically treated microbiota, which is 
represented by the red and pink colored circles, seems to form a separate cluster apart from 
the other circles. A separation between the placebo (blueish) and the probiotic (greenish) 
treated active as well as present microbiota is not clearly visible. 
For a detailed analysis of the differences between the clusters representing the different 
treatments/timepoints an AMOVA was performed as described for unweighted Bray-Curtis 
indices. No significant differences between the present and the active microbiota at either of 
the timepoints/treatments (pcorr > 1 for each comparison) could be detected. Furthermore, 
there were no gender-dependent effects within the active and the present mucosa-associated 
microbiota at the several timepoints, respectively. 
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Table 3-11: Results of the AMOVA for weighted Bray-Curtis indices of the (A) present and the (B) active 
mucosa-associated microbiota. 104 permutations were performed. Cells highlighted in grey show statistical 
significant results after Bonferroni-Holm correction for multiple testing (n = 6). 
Timepoint 
Day 4 Day 46 
Treatment Day 0 Antibiotic Placebo VSL#3 
Day 0 
Day 4 Antibiotic 6e-05 
Day 46 
Placebo 1 0.0016 
VSL#3 0.8691 0.0144 1 
 
Timepoint 
Day 4 Day 46 
Treatment Day 0 Antibiotic Placebo VSL#3 
Day 0 
Day 4 Antibiotic 6e-05 
Day 46 
Placebo 0.5734 6e-05 
VSL#3 0.5486 0.0091 0.5486 
 
Table 3-11 (A) shows the result of the AMOVA for the present mucosa-associated 
microbiota. There is a significant difference between the timepoint ”Day 4” (red and pink 
circles), which is after the antibiotic treatment, and all other three timepoints/treatments. 
However, there are no differences between the initial composition of “Day 0” and the end of 
the study at “Day 46”, regardless of the treatment. Furthermore, there is no difference in the 
comparison of the placebo and the probiotic treatment. The results of the active mucosa-
associated microbiota as depicted in Table 3-11 (B) are the same as within the present 
microbiota. 
Due to some differences between the timepoints a Spearman correlation, a metastats approach 
as well as the search for indicator species were performed. This enables the identification of 
OTUs that are responsible for a separation of the different timepoints and treatments. The 
analyses were performed as described before. Only OTUs with a minimum contribution of 
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Table 3-12: Results of the Spearman correlation of OTUs to weighted Bray-Curtis indices of the present 
and active mucosa-associated microbiota. OTUs with a minimum contribution of 0.5% to the overall 
similarity. Fdr of 0.05. Cells highlighted in grey: OTUs that fulfilled the fdr of 1.0 e-05 and are plotted into the 
biplot in Figure 3-20. 
OTU number/BLAST hit PCo 1 PCo 2 PCo 3 length p.min q.val 
26 Faecalibacterium 0.6401 0.3251 0.5059 0.8783 5.23e-14 1.02e-12 
30 Bacteroides 0.1698 -0.3950 -0.1280 0.4486 4.10e-05 1.85e-04 
32 Parabacteroides 0.0843 0.2940 0.2036 0.3675 4.49e-03 1.17e-02 
33 Bacteroides -0.5925 0.5831 0.2632 0.8719 1.15e-11 1.28e-10 
34 Faecalibacterium 0.3942 0.1577 0.1074 0.4380 4.27e-05 1.85e-04 
38 Faecalibacterium 0.4853 0.2355 0.4637 0.7113 1.34e-07 1.04e-06 
40 Subdoligranulum 0.3518 0.4341 0.0985 0.5674 4.19e-06 2.33e-05 
46 Coprobacillus 0.3055 0.0983 -0.0817 0.3312 2.85e-03 7.93e-03 
47 Blautia 0.7146 0.4581 0.2698 0.8907 1.30e-18 1.02e-16 
48 uncl. Peptostreptococcaceae 0.4467 0.1981 -0.0622 0.4926 1.90e-06 1.14e-05 
51 uncl. Peptostreptococcaceae 0.3923 0.3091 0.0492 0.5019 4.74e-05 1.95e-04 
56 Sutterella 0.2501 0.1078 0.1756 0.3240 2.18e-03 4.37e-02 
65 Blautia 0.7055 0.4085 0.2773 0.8611 5.69e-18 2.22e-16 
76 uncl. Lachnospiraceae 0.6144 0.3952 0.1492 0.7455 1.08e-12 1.40e-11 
81 uncl. Lachnospiraceae 0.3440 0.4725 -0.1679 0.6081 3.32e-07 2.36e-06 
91 uncl. Lachnospiraceae 0.4581 0.3789 0.2592 0.6485 8.90e-07 5.79e-06 
101 Ralstonia -0.2354 -0.2138 -0.3634 0.4829 2.12e-04 8.27e-04 
119 Bacteroides 0.3109 0.2734 0.1330 0.4348 2.28e-03 6.60e-03 
154 uncl. Lachnospiraceae 0.2522 0.1414 -0.1679 0.3344 2.04e-02 4.18e-02 
158 uncl. Firmicutes -0.4051 -0.2311 -0.0385 0.4680 2.33e-05 1.14e-04 
197 Sphingobium -0.1468 -0.1824 -0.2532 0.3449 1.97e-02 4.15e-02 
220 Collinsella 0.1245 0.2853 0.0206 0.3120 6.27e-03 1.58e-02 
231 Eubacterium -0.4178 -0.3720 -0.0760 0.5646 1.12e-05 5.83e-05 
268 Escherichia/Shigella 0.0552 -0.6504 0.3540 0.7425 1.45e-14 3.78e-13 
291 Oscillibacter 0.1478 -0.0023 0.2593 0.2985 1.60e-02 3.47e-02 
294 Streptococcus 0.1616 -0.3041 -0.0808 0.3538 3.01e-03 8.09e-03 
362 uncl. Lachnospiraceae 0.6273 0.2335 0.1391 0.6836 2.44e-13 3.81e-12 
363 Bacteroides 0.0017 0.3233 -0.0269 0.3244 1.35e-03 4.39e-03 
364 Subdoligranulum 0.2653 0.1997 0.0163 0.3325 1.30e-02 2.98e-02 
365 Roseburia 0.5566 0.3410 -0.0629 0.6558 3.83e-10 3.73e-09 
384 Faecalibacterium 0.4861 0.1386 0.1289 0.5216 1.26e-07 1.04e-06 
386 Faecalibacterium 0.2932 0.3472 0.0846 0.4623 4.61e-04 1.71e-03 
612 Prevotella -0.0987 0.1334 -0.3180 0.3587 1.69e-03 5.28e-03 
661 Enterococcus -0.1670 0.0214 -0.3332 0.3733 8.77e-04 2.97e-03 
771 uncl. Incertae Sedis_XI 0.2742 -0.0692 -0.1539 0.3219 9.48e-03 2.31e-02 
904 Prevotella -0.1147 0.1888 -0.2730 0.3512 9.89e-03 2.34e-02 
1252 Coprobacillu 0.1225 -0.2601 0.2062 0.3538 1.56e-02 3.47e-02 
1398 Pseudomonas -0.1545 -0.1034 -0.3336 0.3818 8.61e-04 2.97e-03 
2459 Parasutterella -0.0884 -0.3126 0.0795 0.3345 2.12e-03 6.37e-03 
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To visualize which OTUs are responsible for the clustering of the treatment groups, the 
significantly correlated OTUs were plotted into the biplot. To reduce the number of OTUs 




OTUs listed in Table 3-12 that have a negative value for the PCo 1 tend to be more abundant 
within the antibiotically treated microbiota. A classification revealed that those OTUs belong 
to genera like Bacteroides, Prevotella, Pseudomonas and Ralstonia. OTUs that have positive 
values for all of their three PCos point into the direction opposite of the samples representing 
the antibiotic treatment, these are OTUs having homology to Faecalibacterium, Blautia and 
Figure 3-20: Biplot of weighted Bray-Curtis indices for the present and the active mucosa-associated
microbiota and OTUs correlated to the axes. Correlated OTUs contribute at least 0.5% to the overall
similarity and fulfilled the fdr of 1e-05. "Day 0" (n = 19), present (.....) and active (.....); "Day 4" (after
antibiotic treatment, n = 19), present (.....) and active (.....); "Day 46" placebo group (n = 10), present (.....) and
active (.....); "Day 46" probiotic group (n = 9), present (.....) and active (.....). 
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Subdoligranulum or Lachnospiraceae. Therefore they are more abundant in the normal as 
well as the placebo or probiotically treated microbiota and are rare after antibiotic treatment. 
In addition to the correlation the metastats approach was used. The SIMPER analysis 
identified OTUs with a minimum contribution of 0.5% and was thereby reducing the dataset. 
The results for the comparison between the placebo and the probiotic-treated group at 
timepoint "Day 46" for the active as well as the present mucosa-associated microbiota is 
shown in Table 3-13. 
Table 3-13: Statistical significant results of the metastats analysis comparing the probiotic and the placebo 
treated groups at "Day 46" within the active and the present microbiota. Ratio is relative to placebo. 1000 
permutations were performed. p values after Bonferroni-Holm correction for multiple testing. Appears= present 
in probiotic, but absent in placebo group, Disappears= absent in probiotic group, but present in placebo. n = 10 
within the placebo group, n = 9 within the probiotic group 
Present Bacteria Active Bacteria 
OTU number/BLAST hit ratio (log10) ratio (log10) 
349 Eubacterium 0.020 (-1.706) 
904 Prevotella disappears 
1498 uncl. Prevotellaceae appears appears 
1693 Bacteroides disappears 
 
The AMOVA shown before already revealed that there were no significant differences 
between the placebo and the probiotic group at timepoint "Day 46" within the present as well 
as in the active mucosa-associated microbiota. Therefore it is also expected to find less OTUs 
that are significantly represented differently between the treatment groups (table 3-15). 
OTUs that are represented different between "Day 0" and "Day 4" (antibiotic) as well as 
between "Day 0" and "Day 46" (placebo or probiotic) are listed in Table 3-14. 
Table 3-14: Statistical significant results of the metastats analysis comparing timepoint "Day 0" and "Day 
46" within the present mucosa-associated microbiota. Ratio is relative to "Day 0". 1000 permutations were 
performed. p values after Bonferroni-Holm correction for multiple testing. Disappears = absent at "Day 46", but 
present at "Day 0". Appears = present at "Day 46", but absent at "Day 0". n = 19 ("Day 0"); n = 10 ("Day 46" 
Placebo); n = 9 ("Day 46" Probiotic). Cells highlighted in grey: Indicator species at 97% level. 
Day 4 Day 46 Placebo Day 46 Probiotic 
OTU number/BLAST hit ratio (log10) ratio (log10) ratio (log10)
26 Faecalibacterium 0.018(-1.754) 
34 Faecalibacterium 0.098 (-1.009) 
38 Faecalibacterium 0.012 (-1.936) 
46 Coprobacillus 0.030 (-1.527) 
47 Blautia 0.029 (-1.536) 
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Day 4 Day 46 Placebo Day 46 Probiotic 
OTU number/BLAST hit ratio (log10) ratio (log10) ratio (log10) 
56 Sutterella disappears 
65 Blautia 0.016 (-1.799) 
91 uncl. Lachnospiraceae 0.004 (-2.423) 
158 uncl. Firmicutes 47.882 (1.680) 
231 Eubacterium 3.782 (0.578) 
362 uncl. Lachnospiraceae 0.092 (-1.035) 
364 Subdoligranulum 0.028(-1.546) 
384 Faecalibacterium 0.157 (-0.803) 
1071 Stenotrophomonas disappears 
1398 Pseudomonas appears 
 
The AMOVA already showed no significant differences between the composition of the 
microbiota at "Day 0" compared to the placebo as well as the probiotic group at "Day 46". 
Therefore it is not unexpected that not many differently represented OTUs were found. The 
significant difference between the initial and the antibiotic-treated microbiota shows OTUs 
mainly having identity with the genera Faecalibacterium, Blautia and the family 
Lachnospiraceae. Those OTUs are highly abundant within the untreated microbiota and are 
highly reduced due to the antibiotic treatment. 
This effect could be validated within the indicator species approach. At species level (97% 
identity) the OTUs 26, 34, 38, 47, 65 and 362 were identified as indicator species 
characterizing the difference between the timepoints "Day 0" and "Day 4" and therefore the 
influence of the antibiotic treatment. As shown before, the classification of these OTUs were 
found to have homology with Blautia and Faecalibacterium as well as with Lachnospiraceae. 
For the comparison of the other timepoints/treatments no indicator species could be found. 
This shows that there are no specific OTUs characterizing the probiotic group compared to 
the placebo. Furthermore, these results indicate a good recovery of the microbiota as there are 
no OTUs characterizing the placebo or the probiotically treated microbiota at "Day 46" in 
comparison to "Day 0". The search for indicator species on the genus level (95% identity) 
revealed the same results. 
For the active bacteria the same analyses were performed (Table 3-15). The metastats analysis 
identified OTUs differently represented between the timepoints "Day 0" and "Day 4". 
Comparing the results to the present microbiota (table 3-14) the active microbiota showed 
more different OTUs as there was only one OTU found for the Faecalibacterium and Blautia, 
respectively. On the one hand OTUs that did not appear within the analysis of the present 
microbiota were found. However, those two OTUs (OTU 26 and 65) were also decreased 
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within the active mucosa-associated microbiota due to antibiotic treatment. On the other hand 
OTUs having identity to Bacteroides, Enterococcus and Pseudomonas as well as an OTU 
characterized by Lachnospiraceae seemed to be highly abundant within the antibiotic-treated 
microbiota. The comparison between "Day 0" and "Day 46" did not detect noteworthy 
differences. 
Table 3-15: Statistical significant results of the metastats analysis comparing timepoint "Day 0" and "Day 
46" within the active mucosa-associated microbiota. Ratio is relative to "Day 0". 1000 permutations were 
performed. p values after Bonferroni-Holm correction for multiple testing. Disappears = absent at "Day 46", but 
present at "Day 0". Appears = present at "Day 46", but absent at "Day 0". n = 19 ("Day 0"); n = 10 ("Day 46" 
Placebo); n = 9 ("Day 46" Probiotic). Cells highlighted in grey: Indicator species at 97% level. 
Day 4 Day 46 Placebo Day 46 Probiotic 
OTU number/BLAST hit ratio (log10) ratio (log10) ratio (log10)
26 Faecalibacterium 0.033 (-1.488) 
56 Sutterella 0.020 (-1.696) 
65 Blautia 0.051 (-1.294) 
158 uncl. Firmicutes 50.273 (1.701) 
197 Sphingobium disappears 
198 uncl. Lachnospiraceae 42.686 (1.630) 
231 Eubacterium 5.146 (0.711) 
293 Coprobacillus 0.009 (-2.055) 
365 Roseburia 0.078 (-1.109) 
394 Bacteroides 6.913 (0.084) 
631 Prevotella disappears 
661 Enterococcus 431.868 (2.635) 
668 Brevundimonas disappears disappears 
763 Methylobacterium 0.013 (-1.891) 
1071 Stenotrophomonas 0.002 (-2.694) 
1291 Holdemania appears 
1398 Pseudomonas 51.467 (1.712) 
 
The indicator species approach for the active mucosa-associated microbiota revealed the OTU 
26 to be representative for the difference between the initial healthy and the antibiotically 
treated microbiota. OTU 26, which has identity to Faecalibacterium, was also shown to be an 
indicator species within the present mucosa-associated microbiota. In addition, an OTU 
having identity with Blautia was detected as indicator species on the genus level (95% 
identity). This OTU is highly abundant in the initial healthy microbiota and decreased due to 
the antibiotic treatment. For the comparison between the placebo and the probiotic therapy at 
"Day 46" as well as between the timepoints "Day 0" and "Day 46" no indicator species could 
be found. 
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As described for the luminal samples a Spearman correlation correlating the whole taxa 
(genus) to the axes was performed. 
Table 3-16: Statistical significant results of the Spearman correlation of the taxa on genus level and 
weighted Bray-Curtis indices of the present and the active mucosa-associated microbiota. Taxa with a 
minimum contribution of 0.5% to the overall similarity. Fdr of 0.05. Cells highlighted in grey: Taxa that are 
plotted into the biplot in Figure 3-21 fulfilling the fdr of 0.001. 
Taxon PCo 1 PCo 2 PCo 3 length p.min q.val 
Acinetobacter -0.0563 -0.0983 -0.2718 0.2944 1.03e-02 1.59e-02 
Bacteroides -0.3760 0.1021 0.1180 0.4062 1.18e-04 3.00e-04 
Blautia 0.5797 0.4794 0.0989 0.7588 4.18e-11 5.99e-10 
uncl. Clostridiales 0.4316 0.2863 0.0874 0.5252 4.91e-06 3.01e-05 
Collinsella 0.18764 0.2506 0.1004 0.3287 2.15e-02 2.80e-02 
Coprobacillus 0.2678 -0.1104 0.4042 0.4973 2.46e-05 1.06e-04 
Coprococcus 0.2557 0.3708 -0.0894 0.4592 1.46e-04 3.31e-04 
uncl. Cyanobacteria -0.0446 -0.1323 -0.3289 0.3573 1.06e-03 2.07e-03 
Dorea 0.3568 0.3961 -0.0270 0.5338 3.86e-05 1.51e-04 
Enterobacter -0.0867 -0.4265 0.1310 0.4545 6.68e-06 3.19e-05 
uncl. Enterobacteriaceae -0.0931 -0.3914 0.3475 0.5316 4.99e-05 1.79e-04 
Enterococcus -0.1851 -0.0498 -0.3253 0.3776 1.24e-03 2.32e-03 
Escherichia/Shigella 0.0516 -0.6273 0.3592 0.7247 2.45e-13 1.05e-11 
Eubacterium -0.2400 -0.0889 -0.1749 0.3100 3.03e-02 3.83e-02 
Faecalibacterium 0.6117 0.3421 0.4079 0.8109 1.45e-12 3.12e-11 
Finegoldia 0.1437 -0.2345 -0.10738 0.2952 3.61e-02 4.43e-02 
uncl. Firmicutes -0.3895 -0.2254 0.0186 0.4504 5.52e-05 1.83e-04 
Holdemania -0.3109 0.0278 -0.0287 0.3135 2.28e-03 3.93e-03 
uncl. Incertae_Sedis_XI 0.1222 -0.3188 -0.2321 0.4129 1.64e-03 2.94e-03 
uncl. Lachnospiraceae 0.42900 0.2723 0.1327 0.5251 5.74e-06 3.08e-05 
Methylobacterium -0.0403 -0.1173 -0.2515 0.2805 2.08e-02 2.80e-02 
Oscillibacter 0.2435 0.1169 0.3077 0.4094 2.61e-03 4.32e-03 
Parasutterella -0.0766 -0.2670 -0.0323 0.2796 1.23e-02 1.77e-02 
Peptoniphilus 0.0634 -0.3652 -0.1619 0.4044 1.94e-04 4.18e-04 
uncl. Peptostreptococcaceae 0.3867 0.2554 -0.0901 0.4721 6.41e-05 1.97e-04 
Prevotella 0.0640 0.0009 -0.3828 0.3881 7.90e-05 2.12e-04 
Pseudomonas -0.0869 -0.1168 -0.3850 0.4116 7.02e-05 2.01e-04 
Ralstonia -0.2477 -0.2248 -0.3728 0.5009 1.32e-04 3.16e-04 
Roseburia 0.5007 0.2074 0.1675 0.5672 4.22e-08 3.63e-07 
uncl. Ruminococcaceae 0.0414 0.2818 -0.0114 0.2850 7.16e-03 1.14e-02 
Ruminococcus 0.5625 0.3963 0.1340 0.7010 2.21e-10 2.38e-09 
Sphingobium -0.1146 -0.1938 -0.2669 0.3491 1.23e-02 1.77e-02 
Stenotrophomonas -0.0529 -0.1749 -0.2641 0.3211 1.36e-02 1.88e-02 
Subdoligranulum 0.4367 0.4150 0.0997 0.6106 3.56e-06 2.55e-05 
Sutterella 0.3439 0.1370 0.2551 0.4496 5.38e-04 1.10e-03 
 
 





The correlation of the taxa to the axes shows that the genera Faecalibacterium and Blautia, 
which were also detected within the indicator approach, were highly correlated, showing into 
the direction of the healthy microbiota opposite of the antibiotically treated microbiota. The 
antibiotically treated microbiota seemed to be characterized by Bacteroides, Pseudomonas 
and Ralstonia. Due to the missing difference between the probiotic and the placebo as well as 
the initial group, a taxon on genus level characterising the probiotic one could not be 
identified. 
Figure 3-21: Biplot of weighted Bray-Curtis indices for the present and the active mucosa-associated
microbiota and taxa correlated to the axes. Correlated OTUs contribute at least 0.5% to the overall
similarity and fulfilled the fdr of 0.001. "Day 0" (n = 19), present (.....) and active (.....); "Day 4" (after
antibiotic treatment, n = 19), present (.....) and active (.....); "Day 46" placebo group (n = 10), present (.....) and
active (.....); "Day 46" probiotic group (n = 9), present (.....) and active (.....). 
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Figure 3-22: Changes in relative bacterial amount of the present 
luminal microbiota due to antibiotic treatment and subsequent
placebo or probiotic therapy. All values are normalised to beta actin. 
Median, upper and lower quartile as well as upper and lower whisker are
plotted. Grey (D0): Timepoint "Day 0" (n = 20), Red (D4): Timepoint
"Day 4" after antibiotic treatment (n = 20), blue (D14, D28, D46):
placebo therapy (n = 10), green (D14VSL, D28VSL, D46VSL): probiotic
therapy (n = 10). * indicates significant difference compared to timepoint
"D0" after Bonferroni-Holm correction. 
*
3.3 Real-time PCR approach 
3.3.1 Quantitative results of the luminal microbiota 
The aim of the real-time PCR was to receive an impression of the quantity of the luminal and 
mucosa-associated microbiota. All bacteria and in addition the two phyla Firmicutes and 
Bacteroidetes were measured. The data were normalised to beta actin. With regard to the 
present luminal microbiota 
(Figure 3-22), they 
represented a relative amount 
of 2.9e+06 in median. Due to 
the antibiotic treatment there 
was a significant decrease 
(pcorr = 0.0137) up to 4e+05. 
The placebo and the 
probiotic treatment resulted 
in a higher relative amount 
within the probiotically 
treated group at all three 
timepoints, but the 
differences did not reach any 
significance (pcorr = 0.945 for 
timepoint "Day 46" and pcorr 
= 0.2102 for timepoints "Day 
14" and "Day 28", 
respectively). Since the 
placebo was not significantly 
different from the probiotically treated in either of the timepoints, the placebo and the 
probiotic group were combined and compared to timepoint "Day 0". Neither between "Day 0" 
and "Day 14" (pcorr = 0.3525) nor between "Day 0" and "Day 28" (pcorr = 0.2087) and "Day 0" 
and "Day 46" (pcorr = 0.2087) there were found any significant differences. For luminal 
Firmicutes (median of 1.6e+06) no significant differences between the placebo and the 
probiotic treatment at either of the timepoints could be detected. The antibiotic treatment 
resulted in a significant decrease (pcorr = 0.0137) down to a relative amount of 1.3e+5.
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Figure 3-23: Changes in the relative bacterial amount of present luminal (A) Firmicutes and (B)
Bacteroidetes due to antibiotic treatment and subsequent placebo or probiotic therapy. Normalised to
relative bacterial amount. Relative amount of bacteria, Firmicutes and Bacteroidetes are normalised to beta
actin. Median, upper and lower quartile as well as upper and lower whisker are plotted. Grey (D0): Timepoint
"Day 0" (n = 20), Red (D4): Timepoint "Day 4" after antibiotic treatment (n = 20), blue (D14, D28, D46):
placebo therapy (n = 10), green (D14VSL, D28VSL, D46VSL): probiotic therapy (n = 10). * indicates





When comparing the relative 
amount of Firmicutes to total 
bacteria (Figure 3-23 (A)) the 
decrease due to the antibiotic 
persisted (pcorr = 2.7e-5). The 
differences between the placebo 
and the probiotic therapy were 
not significant at any timepoint, 
but they seemed to converge over 
time. The differences between 
the timepoints and "Day 0" were 
not significant (pcorr > 1). 
Bacteroidetes represented a 
relative amount of 1.4e+05 in 
median, but there were no 
significant differences between 
the placebo and the probiotic 
treatment at either of the three 
timepoints (pcorr = 0.2666 for 
"Day 14" and "Day 28" and pcorr 
= 0.945 for "Day 46", 
respectively), nor due to the 
antibiotic treatment (pcorr = 
0.7983). The antibiotic just 
decreased the relative amount of 
Bacteroidetes to 1.3e+05 (pcorr = 
0.7983). However, when 
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considering Bacteroidetes relative to total bacteria (Figure 3-23 (B)) the ratio increases 
significantly due to the antibiotic treatment (pcorr = 7.6e-06), indicating an overgrow of 
Bacteroidetes. Further there were no significant differences between the timepoint "Day 0" 
and the timepoints "Day 14" (pcorr = 0.2865), "Day 28" (pcorr = 0.996) and "Day 46" (pcorr = 
0.996), respectively. 
3.3.1 Quantitative results of the mucosa-associated microbiota 
Whereas the amount of relative total bacteria (normalised to beta-actin) within the lumen at 
timepoint "Day 0" accounted for 2.9e+06, the active mucosa-associated microbiota showed an 
amount of 2176 and the present mucosa-associated microbiota resulted in 27 bacteria relative 
to beta actin. Concerning the mucosa-associated microbiota there were no significant 
differences due to the treatments (antibiotics vs. placebo vs. probiotics) or timepoints in the 
total active bacteria. Firmicutes (normalised to beta actin) as well as the relative amount of 
Firmicutes to total bacteria did not show any significant differences due to the treatments or 
timepoints. Bacteroidetes only showed a significant increase (pcorr = 0.003388) relative to 
total bacteria due to the antibiotic treatment. Total active mucosa-associated Bacteroidetes 
were not influenced in any way. The present mucosa-associated microbiota with regard to 
total bacteria, Firmicutes and Bacteroidetes as well as Firmicutes and Bacteroidetes relative 
to total bacteria was not altered in any way due to an influence of the antibiotic, the placebo or 
the probiotic at any of the timepoints. 
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4 Discussion 
The aim of the present study was the investigation of the resilience phenomenon of the human 
intestinal microbiota under placebo and probiotic therapy after an antibiotic perturbation. The 
hypothesis was that the administration of a probiotic could result in different microbial 
profiles and an accelerated or more complete recovery. For this aim the intestinal microbiota 
of twenty healthy individuals was perturbed by a three day intake of the antibiotic 
paromomycin (Humatin®). A subsequent probiotic or placebo therapy for 43 days was 
administered to investigate the recovery and possible differences between the two treatment 
groups. This investigation was done by characterizing the microbial profiles of the luminal 
and the mucosa-associated microbiota at several timepoints. The microbial profiles were 
generated by amplifying the 16S rRNA and its corresponding gene and subsequent Sanger or 
454 pyrosequencing. Further a relative quantification of the bacterial amount was done via 
real-time PCR. 
To discuss the results that were obtained within this study, first the changes within the 
microbial profiles due to the antibiotic treatment will be set into the context of the existing 
literature. Afterwards resilience in general and especially the influence of administered 
probiotic VSL#3 will be discussed. Further the impact of VSL#3 on other factors than 
microbial profiles will be elucidated. Finally I will elaborate on the advantages and 
disadvantages of the two sequencing methods, Sanger- and pyrosequencing. 
Most of the published studies used fecal samples to investigate the microbiota of the human 
gastrointestinal tract due to convenience of sampling (Davis et al. 2011; Duncan et al. 2008; 
Shen et al. 2006). Within the present study is was possible to generate microbial profiles of 
the luminal as well as of the mucosa-associated microbiota. This is a big advantage since it 
has not been clarified, whether fecal samples reflect the composition of the mucosal 
microbiota in an adequate way. It is discussed that the mucosa-associated microorganisms 
might be of greater importance to the host due to their interaction with the gut-associated 
lymphoid tissue (GALT) (Eckburg et al. 2005, Zoetendal et al. 2002). The present study is 
therefore the first one to investigate antibiotic-induced changes and the subsequent resilience 
phenomenon of luminal as well as mucosa-associated microbial profiles of the human colon 
and therein comparing placebo to probiotic therapy. 
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4.1 Effect of the antibiotic treatment 
In general the results obtained within this study depend on the site of the colon (luminal 
microbiota or mucosa-associated microbiota). The antibiotic treatment resulted in a significant 
decrease in richness and diversity of the present microbiota at both sites. This was 
accompanied by a decreased abundance of OTUs with homology to the family 
Lachnospiraceae and the genera Faecalibacterium and Blautia. These OTUs were also 
identified as indicator species, therefore characterising the differences between the initial and 
the antibiotically treated microbiota at the luminal as well as the mucosa-associated site. The 
antibiotic treatment of the active mucosa-associated microbiota revealed only a single OTU as 
indicator species, suggesting that the influence of the antibiotic treatment onto the active 
mucosa-associated microbiota is smaller compared to the influence onto the present mucosa-
associated as well as the luminal microbiota. However, also this single OTU was homologous 
to Faecalibacterium. 
The decrease of richness, diversity and abundance of OTUs with homology to 
Faecalibacterium, Blautia and Lachnospiraceae as a result of antibiotic treatment is in 
agreement with other studies. A five day ciprofloxacin treatment resulted in a rapid decrease 
of richness and diversity as well as a reduced abundance of OTUs with homology to the 
luminal Faecelibacterium (Dethlefsen et al. 2008). A four day amoxicillin-clavulanic acid 
treatment decreased the luminal representation of members of Clostridium cluster IV (to 
which Faecalibacterium belongs) and Clostridium cluster XIVa (to which Blautia as well as 
Lachnospiraceae belong) (Young and Schmidt 2004). Reduced richness as well as a decrease 
of Lachnospiraceae was also discovered after a ten day vancomycin treatment within the 
luminal as well as the mucosa-associated microbiota in mice (Robinson and Young 2010). 
Furthermore, Young and Schmidt (2004) observed an increase within Enterobacteriaceae and 
Bacteroides. An increase in Bacteroides could also be detected in the human fecal flora within 
a gnotobiotic mouse model after an amoxicillin-clavulanic acid treatment (Barc et al. 2004). 
Within the present study no increase of Enterobacteriaceae was found. An increased 
abundance of OTUs with homology to Bacteroides could be detected within the luminal and 
within the active mucosa-associated microbiota, but these OTUs were not characterised as 
indicator species. However, Bacteroides is the most abundant genus within the phylum 
Bacteroidetes. The quantitative amount of Bacteroidetes is not altered due to antibiotics as 
measured via qRT-PCR, but increases relative to total bacteria. This assumes a relative 
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overgrowth of Bacteroidetes within the present study. Besides these dominant OTUs the 
antibiotic treatment resulted in additional changes within the mucosa-associated bacteria 
within the present study. A significant increased abundance of OTUs with homology to 
Eubacterium and unclassified Firmicutes as well as a significant decreased abundance of 
OTUs homologous to Sutterella and Coprobacillus within the active and the present mucosa-
associated microbiota was found. Furthermore, the active mucosa-associated bacteria showed 
an increased abundance of OTUs homologous to Enterococcus and Pseudomonas. Given the 
fact that these OTUs were not identified as indicator species and that each OTU consists of 
few sequences, makes them seem negligible on the one hand. On the other hand the sum of 
these OTUs contributes to the significant difference between the initial and the antibiotically 
treated microbial composition found within the AMOVA. 
In conclusion the antibiotic treatment rather caused a decreased abundance of OTUs with 
homology to Faecalibacterium, Blautia and Lachnospiraceae than an increase of OTUs 
homologous to Bacteroides or other harmful bacteria. These changes within the abundance 
are not paromomycin-specific, but are the results of antibiotics in general. The mucosa-
associated microbiota is less influenced by the antibiotic paromomycin than the luminal 
microbiota, which can be attributed to the fact that the applied paromomycin is only poorly 
absorbed (1-3%). 
4.2 Resilience of the intestinal microbiota 
In the present study the mucosa-associated microbiota showed a resilient behaviour of 
richness and diversity. No differences were detected when comparing “Day 0” and “Day 46”. 
Further no OTU was found that was different between the two timepoints. This accounts for 
the present as well as for the active mucosa-associated microbiota. The luminal microbiota 
was resilient according to richness, but not to diversity. Concerning the literature resilience 
depends on duration of the treatment and the antibiotic agent. It is important to note that 
different techniques applied to investigate resilience phenomena may significantly bias the 
outcome of the respective study. Several studies interrogating resilience of human intestinal 
microbiota after antibiotic treatment have been reported all which used different technical 
approaches. On the basis of T-RFLP a seven day clindamycin treatment resulted in an overall 
normalization of the fecal microbiota of otherwise healthy individuals within three months. 
Apart from this some perturbations persisted for two years as specific populations of the 
Bacteroides community did not return (Jernberg et al. 2007). Via culturing it could be shown 
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that richness and number of Bacteroides species returned to pretreatment conditions within 21 
days, but that the species composition (diversity) was still significantly altered after 18 
months (Löfmark et al. 2006). However, one has to consider that culture techniques are not be 
very reliable since they can detect only a small percentage of the dominant anaerobic bacteria 
(Eckburg et al. 2005). Sullivan et al. (2001) described a normalisation of the microbial 
composition a few weeks after the withdrawal of a clindamycin treatment. Measured via 
TTGE the initial luminal composition of healthy individuals that was disturbed by a five day 
course of amoxicillin could be reestablished within 60 days (De La Cochetiere et al. 2005). 
The study by Young and Schmidt (2004) used clone libraries from an acute sinusitis case and 
showed that major bacterial groups were partially restored within 14 days after a single course 
of amoxicillin-clavulanic acid. Although investigated in mice, the generation of clone libraries 
showed nearly baseline values in richness and diversity in the fecal as well as caecal mucosa-
associated microbiota within three weeks cessation of a ten day course of vancomycin 
(Robinson and Young 2010). A clarithromycin and metronidazole treatment administered to 
patients with either gastric or duodenal ulcers immediately decreased the Shannon index of 
the luminal microbiota due to the antibiotic treatment as observed in a 454 pyrosequencing 
approach. Four weeks after cessation of the antibiotic treatment it returned to initial levels 
(Jakobsson et al. 2010). Dethlefsen et al. (2008) also used the 454 pyrosequencing approach 
and described a resilient taxonomic composition within four weeks after a five day course of 
ciprofloxacin in fecal samples of healthy individuals. But it was also reported that several taxa 
failed to recover within six months. 
With regard to specific bacteria Young and Schmidt (2004) showed that two weeks after 
cessation of amoxicillin-clavulanic acid Clostridium cluster XIVa and Clostridium cluster IV 
reappeared, whereas Clostridium cluster XIV showed an accelerated resilience. The present 
study obtained the same results. The OTU with homology to Blautia recovered within 11 days 
after the cessation of the paromomycin treatment as there were no significant differences 
when comparing “Day 14” and “Day 0”. In contrast, the OTU with homology to 
Faecalibacterium was still significantly decreased at “Day 28”, but was finally able to recover 
until “Day 46”. Therefore also the present study identified an accelerated recovery of Blautia, 
which is a member of the Clostridium cluster XIV. The level of OTUs homologous to 
Bacteroides normalised within 11 days after cessation of the antibiotic treatment. A 
normalisation of Bacteroides within a few days had been shown in other studies before 
(Löfmark et al. 2006; Barc et al. 2004; Young and Schmidt 2004). The fact that 
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Faecalibacterium displays a delayed resilience is crucial since Faecalibacterium prausnitzii 
was described as an anti-inflammatory commensal which was also found to be reduced in 
patients with Crohn´s disease as measured by qRT-PCR (Sokol 2008). Lower concentrations 
of Faecalibacterium prausnitzii have been asssociated with a reduced protection of the gut 
mucosa (Jia 2010; Sokol 2009). It has been shown that the antiinflammatory properties 
resulted in decrease of C-reactive protein and significant lower amounts of IL-12 and IFN-γ, 
but in a higher secretion of IL-10 in PBMCs (peripheral blood mononuclear cells). On the 
cellular level as well as in TNBS (trinitrobenzene sulfonic acid) colitis models 
Faecalibacterium fulfilled antiinflammatory properties by secreting metabolites that are able 
to block NF-kB activation and IL-8 production. 
Since one antibiotic course has pervasive effects onto the microbiota it is assumed that a 
repeated antibiotic treatment results in a more severe perturbation. Dethlefsen et al. (2011) 
investigated the effect of two five day courses of ciprofloxacin separated by six months onto 
the luminal microbiota. The microbiota recovered after the first, but was distinct although 
stabilised after the second antibiotic course. The consequences of the altered composition are 
unclear. With regard to disease it has been shown that the risk for Crohn´s disease increased 
with the number of antibiotic courses during childhood (Hviid et al. 2010). Another side 
effect of an antibiotic treatment is the increase of resistance genes that can be monitored for 
up to four years after the cessation of an antibiotic (Jakobsson et al. 2010; Ubeda et al. 2010; 
Sjölund et al. 2005; Sjölund et al. 2003). In addition, there is a high level of transfer of 
resistance genes within the intestine (Lester et al. 2006; Salyers et al. 2006; Scott et al. 2002; 
Shoemaker et al. 2001). 
The present study shows that the pervasive effect of an antibiotic treatment is reversible with 
regard to microbial profiles since at least major groups that account for the microbial profiles 
were able recover in a relatively short time. This is in agreement with several other studies. 
However, resilience depends on the antibiotic agent itself as well as on dose and duration, but 
also on the body site. The present study is one of the few examples where simultaneously 
fecal as well as mucosa-associated microbial profiles were investigated. It has been shown 
that paromomycin treatment resulted in a complete recovery of the mucosa-associated 
microbiota, whereas the luminal microbiota did not show complete resilience with regard to 
diversity. 
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4.3 Effect of the probiotic treatment onto resilience 
It may be assumed that application of probiotics may restore an imbalance within the luminal 
and/or mucosa-associated microbiota caused by antibiotics in an accelerated way. VSL#3 was 
chosen because it is a multistrain probiotic (four Lactobacillus strains, three Bifidobacterium 
strains and one strain of Streptococcus thermophilus) and therefore might be more potent than 
a single strain probiotic (Chapman et al. 2011). Several studies have demonstrated beneficial 
effects of VSL#3 in maintenance of remission in chronic inflammatory bowel disease, 
especially pouchitis and ulcerative colitis (Miele et al. 2009; Kühbacher et al. 2006). In the 
murine model VSL#3 was able to decrease TNBS-induced colitis (Uronis et al. 2010). The 
exact mechanism is unclear, but it seems that gut health is promoted through stimulation 
instead of suppression of the innate immune system. In the murine model local stimulation of 
epithelial innate immune responses by VSL#3 such as an increased production of epithelial-
derived TNF-α and restoration of epithelial barrier function prevented the onset of intestinal 
inflammation (Pagnini et al. 2010). 
Within the present study the SIMPER-reduced dataset of the luminal microbiota comprised 
three OTUs with homology to Streptococcus and three OTUs with homology to 
Lactobacillus, but none with homology to Bifidobacterium. A BLAST (basic local alignment 
search tool) against the 16S ribosomal RNA sequences database of the NCBI (National Center 
for Biotechnology Information) revealed that all three OTUs homologous to Streptococcus 
were indeed homologous to Streptococcus thermophilus, which is a constituent of VSL#3. 
The BLAST against sequences of the Lactobacillus OTUs revealed that only one of the three 
OTUs was a constituent of the applied probiotic, Lactobacillus acidophilus (OTU 1008). The 
other two were identified as Lactobacillus mucosae and Lactobacillus johnsonii. This makes 
Streptococcus thermophilus the highest concentrated strain among the VSL#3 constituents 
within the present study and explains the result that significant differences between the 
placebo and the probiotically treated group as well as between the probiotically treated 
microbiota and the initial composition were only detetctable in abundance of Streptococcus, 
but not of Lactobacillus or Bifidobacterium. The superiority of Streptococcus compared to the 
other seven constituents of VSL#3 was observed before (Pagnini et al. 2010). However, 
Brigidi et al. (2003) observed a significant increase of Lactobacilli, Bifidobacteria and 
Streptococcus thermophilus in the human feces when administered to VSL#3 measured via 
culture and PCR technique. Within the present study no further differences within the luminal 
microbial profiles due to VSL#3 were detected, which is in agreement with several other 
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studies. Brigidi et al. (2003) were not able to detect any significant changes in Enterococci, 
Coliforms, Bacteroides and Clostridium perfringens (Brigidi et al. 2003). In patients with 
irritable bowel syndrome and predominant diarrhea, where VSL#3 is known to sustain 
remission (Huynh et al. 2009; Karimi et al. 2005; Bibiloni et al. 2005), no effect of VSL#3 
onto the luminal microbiota could be shown (Michail and Kenche 2011; Brigidi et al. 2003). 
A study by McNulty et al. (2011) used Bifidobacterium animalis, Lactobacillus delbruekii, 
Lactococcus lactis and Streptococcus thermophilus and therefore two strains that are 
constituents of VSL#3. No significant changes in bacterial species composition were found 
within luminal microbial profiles of human female twin pairs. Even the administered 
probiotic bacteria could not be found. Profiles of gnotobiotic mice harboring a 15-species 
model human gut microbiota, only showed a significant decrease of an Actinobacteria strain 
and an increase of administered B. animalis as well as L. lactis (McNulty et al. 2011). 
Concerning the mucosa-associated microbiota the dataset of the present study contained 
OTUs with homology to Streptococcus thermophilus and Lactobacillus acidophilus, but 
VSL#3 treatment did not result in significant changes of the administered or other bacteria. 
OTUs with homology to Bifidobacterium were not detected at all. Bibiloni et al. (2005) 
investigated the mucosa-associated microbiota of individuals in remission of ulcerative colitis 
that were administered to VSL#3. Streptococcus thermophilus and Bifidobacterium infantis 
could only be detected in three of eleven individuals via DGGE (Bibiloni et al. 2005). 
In general the present study shows that VSL#3 constituents were able to survive the passage 
through the gastrointestinal tract and reach the large bowel, but were not able to colonize the 
mucosa. No influence of VSL#3 was observed on microbial profiles, apart from a significant 
increase of luminal Streptococcus thermophilus, as well as on microbial richness or diversity. 
The luminal colonisation is only temporal as shortly after cessation of the probiotic therapy 
the VSL#3 constituents will be excreted within a few days. This results in the assumption that 
probiotics have to be taken lifelong (Brigidi et al. 2003; Tannock et al. 2000; Venturi et al. 
1999; Chapman et al. 2006). However, also a long term consumption of a probiotic merely 
altered the Lactobacillus population, but did not affect the populations of obligate anaerobic 
bacteria, which are numerically dominant within the fecal microbiota (Tannock et al. 2000).  
The present as well as previously published studies show no influence of VSL#3 on microbial 
profiles. Furthermore, the present study observed that resilience is independent of probiotic 
therapy, or at least independent of VSL#3, when administered subsequently to antibiotic 
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treatment. Another possibility is the concomitant administration of anti- and probiotics. In a 
study by Jernberg et al. (2005) fecal samples from eight healthy volunteers allocated to a 
seven day course of clindamycin and a concomitant 14 day course with probiotic (containing 
L. acidophilus, L. paracasei and B. lactis) or normal yoghurt were investigated via cultivation 
experiments. 14 days after cessation of antibiotics (and 7 day after cessation of probiotics) the 
fecal microbiota of the placebo group was still repressed, whereas the probiotically treated 
microbiota had mainly recovered to pretreatment levels. Another study showed that the 
numbers of Lactobacillus as well as Bifidobacterium were not significantly altered after a 
concomitant 7 day treatment with clindamycin and a probiotic (one Bifidobacterium and two 
Lactobacillus strains) treatment, but significantly decreased within the fecal microbiota of the 
placebo group (Sullivan et al. 2003). A seven day course with amoxicillin/clavulanate 
concomitant to a three week administration of probiotic Bifidobacteria and Lactobacilli 
resulted in a less disturbed microbiota according to T-RFLP and culture data and a more 
similar composition to baseline than the placebo treated group (Engelbrektson et al. 2009). In 
contrast a seven day course of amoxicillin concomitant to a 14 day course of a multistrain 
probiotic (that further contained inulin enriched oligofructose and therefore not only the 
bacteria, but also nutrients for the bacteria) only resulted in an increase in Enterococci and a 
less frequent bowel movement within the probiotically treated group of otherwise healthy 
volunteers. At the end of the study no differences compared to day 0 within the probiotic as 
well as in the placebo group were discovered (Koning et al. 2008). The mechanisms why the 
concomitant application of antibiotics and probiotics should be more beneficial than the 
subsequent use are speculative. It is assumed that the beneficial effect of probiotics is due to 
the metabolism of supplemented bacteria. Probiotic bacteria can metabolise luminal 
components and thereby generate substrates that may act as nutrients for other bacteria. Due 
to metabolism, the physical environment changes to a preferential one with lower pH 
(Engelbrektson et al. 2009). However, these mechansims are generally described for the 
benefit of probiotic bacteria and do not explain the possible advantage of a concomitant 
antibiotic/probiotic therapy to a subsequent one. 
4.4 Alternative effects of probiotic therapy 
VSL#3, but also Lactobacillus and Bifidobacterium infantis alone, have been described to 
exhibit beneficial effects on bloating and result in a reduced flatulence as well as a slower 
transit time in patients suffering from irritable bowel syndrome with bloating (Ringel-Kulka 
et al.; Kim et al. 2005; Kim et al. 2003). Furthermore, VSL#3 normalised the bowel habits 
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and stool consistency in patients with irritable bowel syndrome or functional diarrhea (Brigidi 
et al. 2001). Within the present study no questionnaire was compiled asking for bowel 
functions and gastrointestinal symptoms. However, none of the study participants reported 
indisposition or even diarrhea. The absence of any reported gastrointestinal symptoms could 
therefore indicate that the gut microbiota is functionally unaffected by antibiotics as well as 
probiotics (Dethlefsen et al. 2011). 
The functional component can be linked to beneficial metabolites of supplemented bacteria. 
As mentioned previously, probiotics metabolise luminal components thereby generating 
substrates or a physical environment which is preferred by other bacteria central to the 
broader stability of the microbiota. Especially the concentration as well as the distribution of 
organic compounds like carbohydrates, short chain fatty acids (SCFA) and bile acids can be 
significantly altered due to changes of the gut microbiota (Macfarlane and Mcfarlane, 2011; 
Högenauer et al. 1998). As shown in the murine model a probiotic treatment did not result in 
significant changes within bacterial composition, but within expression of microbiome-
encoded enzymes, which were prominently involved in the carbohydrate metabolism 
(McNulty et al. 2011). The colonic bacteria, but mainly anaerobes, ferment unabsorbed 
carbohydrates as an energy source and produce lactic acid as well as the SCFAs butyrate, 
propionate and acetate (Floch 2010; Cummings et al. 1987). The SCFAs are absorbed and can 
be directly used by colonic mucosal epithelial cells with butyrate being the most important 
and preferred source of colonocytes. Propionate and acetate are systemically used within the 
body (Cook et al. 1998; Roediger et al. 1980; McNeil et al 1978). The production of SCFAs is 
important as it has been shown that a reduction of SCFA as a result of reduced levels of 
colonic anaerobes could directly lead to functional disorders of the colonic mucosa (Toping et 
al. 2001). Butyrate and propionate were described to have aniinflammatory capacities and 
also seemed to be beneficial by inhibiting NF-κB (Tedelind et al. 2007; Segain et al. 2000). 
The SCFAs can reduce the pH in the colon and thereby inhibit the growth of pathogenic 
bacteria as well as increase the calcium uptake by increasing the solubility of the calcium 
(Wong and Jenkins 2007; Van den Heuvel et al. 1999). Streptococcus thermophilus was 
identified to increase the values of propionate and butyrate (Rizkalla et al. 2000). Acetate and 
lactate can be produced by Streptococcus as well as by Lactobacillus and by Bifidobacteria, 
which can then be converted into butyrate and propionate through cross-feeding by other 
bacteria (e.g. Eubacterium halii, Faecalibacterium prausnitzii) (Belenguer et al. 2006; 
Morrison et al. 2006; Duncan et al. 2004). These studies lead to the conclusion that the effects 
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of probiotics target on metabolic functions rather than microbial composition. It would 
therefore be interesting to measure metabolites like SCFA and to investigate the influence of a 
subsequent antibiotic and VSL#3 treatment on these. 
4.5 General discussion of sequencing methods 
The two sequencing methods used in the present study were the chain termination sequencing 
according to the method of Sanger and the 454 pyrosequencing approach. Both have in 
common that DNA or RNA is extracted from a sample. PCR primer then bind to conserved 
regions of the 16S rRNA gene amplifying the intermediate variable regions. Therefore both 
methods can be effected by biased PCR amplification of microbial populations in the sample. 
In addition, the Sanger method requires a cloning step that is missing in the pyrosequencing 
approach, making the latter less error-prone. A further advantage of pyrosequencing is the 
immense output of averaged 200.000 reads obtained per single run on a GS-FLX. Within the 
present study, sample pooling allowed for the simultaneous sequencing of 30 to 40 samples, 
thereby generating 5000 reads per sample within a single run. On the capillary Sanger 
sequencer one run generated 96 sequences and therefore half a sample. A further disadvantage 
is that the Sanger method limits the ability of discovering less-abundant members of a 
microbial community due to the fact that only 192 clones have been picked. The incomplete 
profile was also visible in low coverage and for some samples quite steep rarefaction curves. 
On the other hand it can be stated that longer 16S rRNA gene sequences enable the highest 
possible degree of taxonomic resolution. Nevertheless, the sequencing according to the 
method of Sanger was shown as a technique that is able to reveal significant shifts within the 
community structure. The pyrosequencing approach generates a much larger amount of 
sequences at lower costs and therefore gives a more complete picture, but there is less 
phylogenetic information generated from a single read due to the short length (Margulies et al. 
2005). However, it has been shown that reads spanning variable regions of the 16S rRNA 
gene are highly informative and that it is even better to generate more short sequences than 
less longer sequences (Liu et al. 2007). Several papers have already demonstrated the power 
of pyrosequencing (Sogin et al. 2006; McKenna et al. 2008). In the present study the V1 to 
V4 and the V1 to V2 regions were used for the Sanger and the pyrosequencing approach, 
respectively. The V1 to V4 region was chosen as it has been shown that segments around the 
V2 and V4 region have the lowest error rate (Wang 2007). For pyrosequencing the V1 to V2 
region was amplified as the V2 is the longest among all nine variable regions. Furthermore, 
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V1 and V2 are closer to each other than V3 and V4, which enabled sequencing of two 
consecutive regions (Baker et al. 2003). 
A critical point within analysis is the fact that different amounts of reads per sample were 
generated within the pyrosequencing approach. It is common to normalise the reads to the 
lowest number found in all samples. Normalisation per se has to be performed since it has 
been observed that the number of false OTUs is correlated with the number of sequences. It 
enables all sequences to be wrong with same probability, whereas most of the false OTUs 
seemed to be chimera that could not be detected before. Normalisation itself is a random 
selection, which is not an ideal solution (Schloss et al. 2009). However, it has little influence 
on efficiency of 16S rRNA gene discovery when working with thousands of reads (Hale et al. 
2009; Harris et al. 2010). Further it has been shown that 1000 sequences per sample are 
adequate for analysis (Momozawa et al. 2011). Within the present study it was possible to 
generate 1506 denoised sequences per sample, which allowed for a reliable analysis. 
4.6 Outlook 
The present study is the first to investigate resilience of the luminal as well as the mucosa-
associated microbiota of the human colon after a subsequent antibiotic and probiotic therapy 
with newest technology. It was shown that microbial richness as well as diversity within the 
present and active mucosa-associated microbiota was resilient after cessation of a three day 
course of paromomycin. In contrast, the luminal microbiota was resilient in richness, but not 
in diversity as it was not able to recover to pretreatment values within 43 days. OTUs that 
were significantly altered due to antibiotic treatment were able to restore until the end of the 
study within both body sites. Resilience was probiotic-independet. Except for a significant 
increase of VSL#3 constituent Streptococcus thermophilus within the luminal microbiota, no 
significant differences in microbial profiles were found as a result of probiotc therapy within 
the luminal as well as the mucosa-associated microbiota. 
However, several studies reported benefits for diseased people when administered VSL#3. 
VSL#3 was described as a good alternative within sustainment of remission in IBD and 
prevention of onset or relapses in pouchitis (Mimura et al. 2004; Bibiloni et al. 2005; Sood et 
al. 2009; Holubar et al. 2010). Patients had a higher quality of life (Guandalini et al. 2010; 
Bowen et al. 2007; Delia et al. 2007; D´Souza et al. 2002) due to VSL#3-dependent reduction 
of bleeding, bloating and flatulence (Tursi et al. 2010; Gionchetti et al. 2007; Kim et al. 
2005). Since the microbial composition is not or only to a very small extend altered by 
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probiotics, the beneficial effects have to be caused by other factors. Studies have shown 
effects of probiotic treatment on bacterial metabolites and expression of microbiome-encoded 
enzymes (McNulty et al. 2011; Okombo et al. 2010; Belenguer et al. 2006). The metabolites 
themselves were discussed to have an influence on molecular level (Tedelind et al. 2007; 
Segain et al. 2000). A direct effect of probiotics on molecular level was also observed and 
resulted in a protected epithelial barrier, stimulation of innate immunity and less 
proinflammatory cytokines (Dai et al. 2012; Pagnini et al. 2010; Ng et al. 2010; O´Mahoney 
et al. 2005; McCarthy et al. 2003). Although the molecular mechanisms of probiotic-induced 
beneficial effects remain poorly understood they somehow contributed to human health. 
In conclusion it seems promising to look for functional rather than compositional changes of 
the human gut microbiota when studying resilience and the influence of probiotics. Future 
studies should address questions related to alterations of metabolies like SCFA and 
metabolism-dependent enzymes as well as further elucidate molecular mechansims. Also 
basic knowledge of probiotics like optimal dose, duration of treatment and composition of 
administered probiotic is completely lacking as research is just at the very beginning. The 
understanding of how probiotics contribute to human health will eventually result in a more 
adequate treatment of individuals suffering from harm- and painful diseases and will therefore 
enable a higher quality of life. 
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5 Summary 
Each human being harbors an individual and quite stable community of microorganisms 
within the gastrointestinal tract, whereas the highest density can be found in the large 
intestine. The ability of the microbiota to recover after an external perturbation is referred to 
as the resilience phenomenon. 
The aim of this study was the investigation of resilience of the colonic microbiota after a three 
day course of antibiotic perturbation with paromomycin and a subsequent therapy with 
probiotic VSL#3 or placebo over a period of 43 days. For this observation 16S rRNA gene 
libraries of the luminal as well as 16S rRNA and 16S rRNA gene amplicon libraries of the 
mucosa-associated microbiota were generated and sequenced via sequencing techniques 
according to the method of Sanger and pyrosequencing, respectively. This enabled the 
establishment of microbial profiles at different timepoints throughout the whole study. A 
quantitative real-time PCR was performed additionally. 
Antibiotic treatment resulted in decrease of richness and diversity within the luminal as well 
as the present and active mucosa-associated microbiota. This was underlined by a decrease in 
abundance of Operational Taxonomic Units (OTUs) homologous to Lachnospiraceae, 
Faecalibacterium and Blautia, which were identified as indicator species. Subsequent 
resilience was characterised by a complete recovery of richness and diversity of the mucosa-
associated microbiota. Diversity of the luminal microbiota was not restored to pretreatment 
levels until the end of the study. Abundances of OTUs altered due to antibiotc treatment 
recovered in the course of the study in the luminal as well as the mucosa-associated 
microbiota. Probiotc VSL#3 had no influence on resilience of diversity and richness. Apart 
from a significant increase of luminal VSL#3 constituent Streptococcus thermophilus no 
further changes of microbial profiles were observed in either the luminal or the mucosa-
associated microbiota due to probiotic therapy. 
Probiotic VSL#3 did not result in accelerated resilience of microbial composition after 
antibiotic perturbation. It must be emphasized that VSL#3 was shown to improve bowel 
function and symptoms in diseased individuals as well as result in an increase of short chain 
fatty acids and beneficial effects on molecular level within other studies. VSL#3 is therefore 
assumed to influence function rather than composition of the colonic microbiota. Future 
studies should address functional-related questions, thereby elucidating possible mechanisms 
by which probiotics confer a health benefit to the human host. 
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6 Zusammenfassung 
Jeder Mensch besitzt eine individuelle und relativ stabile Gemeinschaft von Mikroorganismen 
innerhalb des Gastrointestinaltraktes, wobei die höchste Dichte innerhalb des Dickdarmes zu 
finden ist. Die Fähigkeit der Mikrobiota nach einer Schädigung zu regenerieren wird als 
Resilienz-Phänomen bezeichnet. 
Ziel dieser Studie war die Untersuchung der Resilienz der humanen Dickdarmmikrobiota 
nach einer drei-tägigen Perturbation mit dem Antibiotikum Paromomycin und anschließender 
43-tägiger Probiotika- oder Plazebobehandlung. Dafür wurden 16S rRNA-Genbibliotheken 
der luminalen sowie 16S rRNA und 16S rRNA-Gen Amplikonbibliotheken der mukosa-
assoziierten Mikrobiota generiert und mittels Sanger- bzw. Pyrosequenzierung analysiert. 
Dies ermöglichte die Erstellung von mikrobiellen Profilen zu unterschiedlichen Zeitpunkten 
der Studie. Zusätzlich wurde eine quantitative real-time PCR durchgeführt. 
Die Antibiotikabehandlung resultierte in einer Abnahme des Artenreichtums und der 
-diversität der luminalen sowie der mukosa-assoziierten Mikrobiota. Dies wurde durch eine 
Abnahme in der Abundanz von Operational Taxonomic Units (OTUs) mit Homologie zu 
Lachnospiraceae, Faecalibacterium und Blautia, die auch als Indikator Spezies identifiziert 
wurden, unterstrichen. Die nachfolgende Resilienz war durch eine vollständige Regeneration 
von Artenreichtum und -diversität der mukosa-assoziierten Mikrobiota gekennzeichnet. Die 
Diversität der luminalen Mikrobiota konnte bis zum Ende der Studie das anfänglichen Niveau 
nicht erreichen. Die durch die Antibiotikagabe veränderten Abundanzen der OTUs der 
luminalen wie auch der mukosa-assoziierten Mikrobiota erholten sich im Laufe der Studie. 
Das Probiotikum VSL#3 hatte keinen Einfluss auf die Resilienz von Artenreichtum und 
-diversität. Außer einem signifikanten Anstieg des im VSL#3 enthaltenen Streptococcus 
thermophilus im Lumen, konnten keine weiteren Veränderungen in den mikrobiellen Profilen 
durch die Probiotikagabe beobachtet werden. 
Das Probiotikum VSL#3 hatte keinen Einfluss auf die Resilienz der mikrobiellen 
Zusammensetzung nach Antibiotikagabe. Allerdings wurde gezeigt, dass VSL#3 Gabe eine 
Verbesserung von Darmfunktion und Symptomen bei erkrankten Individuen sowie einen 
Anstieg von kurzkettigen Fettsäuren und günstige Einflüsse auf molekularer Ebene zur Folge 
hatte. Daher wird angenommen, dass VSL#3 eher die Funktionen als die Zusammensetzung 
der Mikrobiota beeinflusst. Zukünftige Studien sollten funktionell bedingte Fragestellungen 
beantworten, die es ermöglichen die Mechanismen, durch die Probiotika ihre vorteilhafte 
Wirkung hervorrufen, aufzuklären. 
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7 Appendix 
7.1 Characteristics of study participants 
Table 7-1: Characteristics of study participants. 





1 26 Female 1.66 63 22.9 
2 27 Female 1.75 63 20.6 
3 26 Female 1.72 69 23.3 
4 28 Male 1.74 68 22.5 
5 25 Male 1.79 70 21.8 
6 30 Male 1.80 85 26.2 
7 26 Female 1.75 80 26.1 
8 27 Female 1.82 71 21.4 
9 30 Female 1.78 67 21.1 
10 26 Female 1.70 60 20.8 
11 28 Female 1.78 74 23.4 
12 24 Female 1.73 59 19.7 
13 30 Male 1.87 75 21.4 
14 29 Female 1.70 66 22.8 
15 23 Male 1.85 85 24.8 
16 25 Female 1.81 65 19.8 
17 23 Female 1.57 59 23.9 
18 24 Female 1.60 62 24.2 
19 25 Female 1.77 98 31.3 
20 26 Female 1.77 80 25.5 
 
7.2 Individual values for alpha-diversity of the luminal microbiota 
Table 7-2: Individuals values for alpha diversity of the luminal microbiota. 










0 165 0.5515 98 323 4.23 
4 165 0.6485 77 242 3.74 
14 168 0.6607 79 224 3.77 
28 161 0.6584 78 192 3.83 
46 169 0.6036 91 261 4.00 
2 
0 169 0.5325 107 327 4.45 
4 156 0.8269 38 155 2.71 
14 162 0.7037 71 212 3.71 
28 156 0.3910 109 556 4.22 
46 155 0.2000 131 1656 4.66 
 7 APPENDIX 
93 










0 178 0.5674 106 431 4.41 
4 159 0.6981 61 222 2.99 
14 161 0.4969 102 507 4.36 
28 160 0.6000 83 335 3.94 
46 168 0.5298 101 443 4.27 
4 
0 160 0.5750 90 280 4.06 
4 144 0.5764 71 437 3.44 
14 149 0.4497 92 566 3.79 
28 128 0.4922 81 341 4.10 
46 151 0.5033 97 405 4.34 
5 
0 149 0.1275 139 1071 4.91 
4 155 0.3935 108 594 4.27 
14 171 0.4035 121 550 4.51 
28 173 0.7283 76 159 3.94 
46 170 0.6647 86 175 4.03 
6 
0 156 0.3141 122 689 4.63 
4 146 0.5616 85 287 4.12 
14 153 0.3725 110 1250 4.43 
28 156 0.5321 88 351 3.73 
46 160 0.1938 138 1170 4.78 
7 
0 149 0.2685 122 858 4.67 
4 147 0.6667 68 215 3.62 
14 152 0.6447 74 253 3.84 
28 159 0.3899 113 695 4.46 
46 148 0.3716 105 961 4.37 
8 
0 162 0.4691 110 354 4.48 
4 152 0.4013 103 1127 4.23 
14 161 0.4721 100 457 4.04 
28 170 0.4706 101 769 3.83 
46 152 0.4605 91 755 3.79 
9 
0 160 0.3938 120 453 4.66 
4 149 0.7450 55 143 3.14 
14 148 0.6284 77 226 3.89 
28 136 0.4926 87 322 4.17 
46 167 0.5808 90 358 4.02 
10 
0 125 0.5120 80 233 4.13 
4 170 0.3471 127 999 4.64 
14 163 0.4479 104 605 4.03 
28 173 0.7110 68 204 3.09 
46 141 0.7234 52 176 2.87 
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0 148 0.5338 92 248 4.24 
4 161 0.6957 61 208 2.56 
14 147 0.5034 90 353 4.06 
28 166 0.4578 108 609 4.37 
46 135 0.2815 110 627 4.57 
12 
0 161 0.2795 132 738 4.77 
4 179 0.8156 47 135 2.66 
14 161 0.5839 87 529 4.06 
28 171 0.4620 113 462 4.42 
46 133 0.3383 107 380 4.59 
13 
0 147 0.1905 130 1008 4.80 
4 164 0.2988 127 1220 4.57 
14 153 0.4118 108 472 4.40 
28 141 0.2128 121 1139 4.70 
46 152 0.2105 134 683 4.84 
14 
0 167 0.1257 153 2799 4.97 
4 169 0.3254 131 936 4.72 
14 169 0.4970 103 460 4.07 
28 174 0.6839 76 211 3.48 
46 178 0.6685 74 264 3.13 
15 
0 171 0.6082 101 202 4.36 
4 173 0.8844 27 217 1.75 
14 161 0.4907 99 763 4.20 
28 137 0.2774 116 463 4.69 
46 168 0.4167 112 706 4.24 
16 
0 167 0.0419 163 4403 5.08 
4 142 0.0423 139 2434 4.93 
14 150 0.0733 144 2062 4.95 
28 170 0.1824 153 891 4.99 
46 173 0.2023 153 941 4.98 
17 
0 152 0.1118 143 1274 4.94 
4 152 0.6184 72 279 3.47 
14 159 0.2453 132 925 4.71 
28 150 0.2067 130 910 4.76 
46 150 0.2667 117 1616 4.38 
18 
0 164 0.4268 112 509 4.34 
4 173 0.7225 73 154 3.61 
14 164 0.7927 52 132 3.19 
28 163 0.6626 74 260 3.67 
46 161 0.4783 101 599 4.24 
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0 162 0.5988 89 297 4.14 
4 185 0.9459 20 28 1.74 
14 168 0.7798 60 127 3.44 
28 176 0.8750 48 69 3.17 
46 151 0.7152 63 153 3.50 
20 
0 174 0.5402 102 453 4.29 
4 153 0.4118 107 608 4.40 
14 179 0.7486 58 256 3.04 
28 172 0.7384 57 387 2.88 
46 155 0.7097 52 1042 2.52 
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7.3 Individual values for alpha-diversity of the mucosa-associated microbiota 
Table 7-3: Individual values for alpha diversity of the mucosa-associated microbiota. 
 Present microbiota Active microbiota 



















0 1506 0.9216 277 424 4.64 1506 0.9197 219 421 3.64 
1 4 1506 0.9641 152 197 3.63 1506 0.9097 256 543 4.40 
46 1506 0.9429 185 344 4.03 1506 0.8997 229 768 3.89 
0 1506 0.9449 181 343 3.98 1506 0.9177 201 494 3.70 
2 4 1506 0.9708 60 297 1.82 1506 0.9529 137 223 2.90 
46 1506 0.9695 133 176 3.55 1506 0.9031 228 620 3.85 
0 1506 0.9143 237 555 4.23 1506 0.8805 275 946 4.31 
3 4 1506 0.9588 120 309 3.28 1506 0.9728 87 146 2.38 
46 1506 0.9442 162 291 3.51 1506 0.9309 170 413 2.98 
0 1506 0.9369 207 347 4.27 1506 0.9363 170 368 2.70 
4 4 1506 0.9661 135 184 3.44 1506 0.9396 193 307 3.89 
46 1506 0.9216 201 501 3.68 1506 0.8938 254 664 3.98 
0 1506 0.9389 186 360 4.07 1506 0.8858 256 956 4.20 
5 4 1506 0.9675 84 252 2.75 1506 0.9489 155 301 3.63 
46 1506 0.9542 130 343 3.38 1506 0.9017 211 684 3.66 
0 1506 0.9343 201 374 3.90 1506 0.8811 278 776 4.14 
6 4 1506 0.9748 87 165 2.79 1506 0.9548 119 372 3.15 
46 1506 0.9403 184 351 3.94 1506 0.9044 230 611 3.95 
0 1506 0.9402 213 347 3.77 1506 0.9396 164 368 2.67 
7 4 1506 0.9655 103 163 2.42 1506 0.9489 148 265 3.13 
46 1506 0.9582 158 214 3.33 1506 0.9309 197 364 3.64 
 




 Present microbiota Active microbiota 



















0 1506 0.9701 95 153 2.59 1506 0.9462 122 338 2.47 
8 4 1506 0.9641 99 278 2.92 1506 0.9714 88 201 3.12 
46 1506 0.9535 147 268 2.99 1506 0.9296 182 646 3.71 
0 1506 0.9416 194 347 3.60 1506 0.9064 233 752 3.60 
9 4 1506 0.9562 127 229 2.77 1506 0.9774 56 168 1.53 
46 1506 0.9509 146 275 3.51 1506 0.9449 141 303 2.55 
0 1506 0.9343 177 371 3.62 1506 0.9044 219 791 3.82 
11 4 1506 0.9442 162 271 3.16 1506 0.9402 150 400 2.89 
46 1506 0.9548 174 241 3.84 1506 0.9548 135 243 3.05 
0 1506 0.9150 246 478 4.22 1506 0.8758 279 806 3.92 
12 4 1506 0.9794 50 116 1.67 1506 0.9794 53 146 1.94 
46 1506 0.9416 158 413 3.26 1506 0.9177 199 453 3.36 
0 1506 0.9515 189 286 4.09 1506 0.8964 263 680 4.21 
13 4 1506 0.9675 93 177 2.70 1506 0.9661 92 172 1.93 
46 1506 0.9336 238 362 4.40 1506 0.9124 264 475 4.60 
0 1506 0.9668 112 206 3.30 1506 0.9343 172 403 3.42 
14 4 1506 0.9708 76 171 2.45 1506 0.9595 92 295 2.68 
46 1506 0.9708 108 187 2.98 1506 0.9323 160 418 3.32 
0 1506 0.9456 168 343 3.37 1506 0.8924 267 675 4.09 
15 4 1506 0.9515 137 231 2.60 1506 0.9356 202 313 3.33 
46 1506 0.9336 171 462 3.14 1506 0.8639 277 1227 4.02 
0 1506 0.9708 108 164 2.29 1506 0.9568 104 226 2.11 
16 4 1506 0.9270 169 485 2.82 1506 0.9104 210 621 3.37 
46 1506 0.9575 195 248 4.08 1506 0.9064 255 608 4.43 
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 Present microbiota Active microbiota 



















0 1506 0.9708 115 149 2.83 1506 0.9628 91 201 1.96 
17 4 1506 0.9774 75 122 2.60 1506 0.9728 98 149,25 3.19 
46 1506 0.9455 144 339 2.82 1506 0.9316 159 378 2.86 
0 1506 0.9655 105 179 2.23 1506 0.9641 101 163 2.12 
18 4 1506 0.9867 46 84 2.10 1506 0.9748 68 156 2.43 
46 1506 0.9615 114 232 3.04 1506 0.9256 185 551 3.69 
0 1506 0.9681 125 176 3.43 1506 0.9661 96 255 2.61 
19 4 1506 0.9861 46 72 2.06 1506 0.9807 47 128 1.80 
46 1506 0.9661 100 171 2.89 1506 0.9562 111 254 2.69 
0 1506 0.9178 210 687 4.11 1506 0.8692 285 1204 4.37 
20 4 1506 0.9801 55 142 2.30 1506 0.9807 53 155 2.06 
46 1506 0.9588 120 309 3.70 1506 0.9190 209 530 4.14 
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